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Abstract 
 
 
Our laboratory recently reported that treatment with the d-amino acid containing peptide 
HYD1 induces necrotic cell death in multiple myeloma (MM) cell lines. Due to the intriguing 
biological activity and promising in vivo activity of HYD1, we pursued strategies for increasing 
the therapeutic efficacy of the parent linear peptide. These efforts led to the development of a 
cyclized peptidomimetic, MTI-101, with increased in vitro activity and robust in vivo activity as 
a single agent using two myeloma models that consider the bone marrow microenvironment. 
MTI-101 treatment resulted in mechanistically similar hallmarks of HYD1 induced cell death, 
namely the generation of ROS, depletion of ATP levels, and failure to activate caspase-3. 
Moreover, MTI-101 was shown to be cross-resistant in the HYD1 acquired resistant H929-60 
cell line that was previously developed in our laboratory. In the present study, we pursued an 
unbiased chemical biology approach using biotinylated peptide affinity purification and LC-
MS/MS analysis to identify binding partners of MTI-101. Using this approach, CD44 was 
identified as a predominant binding partner. Using an ELISA based assay, we showed that 
biotinylated peptide bound to full length recombinant human CD44 in a concentration dependent 
manner. Reducing the cell surface expression of CD44 was accompanied by the activation of 
caspase-3 and cell death was observed in the NCI-H929 and U266 MM cell lines, indicating that 
MM cells require CD44 expression for survival. Ectopic expression of CD44s correlated with 
increased binding of the FAM-conjugated peptide in the 8226 MM cell line, and this was further 
corroborated using CD44 knockout mice which also showed less peptide binding compared to 
  xii 
wild-type.  However, ectopic expression of CD44s was not sufficient to increase the sensitivity 
to MTI-101 induced cell death.  Mechanistically, we show that MTI-101 induced a pro-survival 
signal through the activation of Erk1/2 and that CD44 formed a complex with Pyk2. These data 
corroborate with that of which was previously observed with the parental peptide being a partial 
agonist and inducing an autophagic survival signal. With respect to cell death, we showed that 
CD44 forms a complex with known death inducing proteins caspase-8, caspase-10, Rip1, Rip3, 
Drp1, TNFAIP8, and PGAM5. Furthermore, we demonstrated that MTI-101 induced 
mitochondrial fission which may be modulated by a Rip1, Rip3 or Drp1 dependent and 
independent pathway.   Finally, we show that MTI-101 has robust activity as a single agent in the 
SCID-Hu bone implant and 5TGM1 in vivo model of multiple myeloma. Together these data 
continue to support the further development of this class of compounds as well as identify CD44 
as a therapeutic target for the treatment of MM. 
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Chapter I. Introduction 
 
1.1 Drug Discovery 
 The use of pharmaceutics dates back thousands of years to early human civilization. 
Early folk medicines were derived from plants, minerals, and animal products. These early 
medicines were not only used to treat diseases but also played an important role in religious rites 
and rituals1,2.  The ancient Egyptian, Greek, and Chinese civilizations were among the first to 
experiment with natural products and extracts to treat physical ailments. During this time 
apothecaries, through crude experimentation, would isolate, extract, or mix various herbs and 
animal products in an attempt to formulate new medicines to treat disease. Examples of ancient 
pharmaceuticals include: reserpine as an anti-hypertensive, willow bark as an anti-pyretic, 
ginseng as a stimulant, ephedrine as an anti-asthmatic, aloe to treat wounds, henbane as an anti-
venom, and fennel and linseed as a laxative1-3. Much of the ancient medicines were lost upon 
Western culture until the Renaissance era brought about a renewed interest and study in 
medicine, anatomy, and physiology. However, it was not until the Industrial Revolution that 
there were a number of major scientific breakthroughs that brought new medicines to the public. 
Among these were pivotal studies done by Edward Jenner, who through studying smallpox, was 
able to develop the world’s first vaccine. This breakthrough was followed by Louis Pasteur and 
his discovery of the germ theory of disease as well as Paul Ehrlich’s pioneer research in 
microbiology and antisera which led to new methods in tissue staining and the first 
chemotherapeutic agent arsphenamine, to treat syphilis. Despite these advances, there were only 
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a few new drugs that were widely used by the early twentieth century namely, aspirin, digitalis, 
quinine, mercury, arsphenamine, ipecacuanha, and sulfanilamide1. Then in 1928 Alexander 
Fleming discovered arguably the most important drug of the twentieth century, that being 
Penicillin. It was also during this time that chemists began to synthesize and randomly screen 
compounds thus giving birth to the pharmaceutical industry. With the rise of the pharmaceutical 
industry came a need to establish a standard of measure to evaluate the safety and efficacy of 
novel agents as well as a governing body to regulate and enforce such measure. This led to the 
creation of the Food and Drug Administration (FDA) and the beginning of large scale random 
clinical trials. By the 1970s and early 1980s, x-ray crystallography and recombinant DNA 
technology were being widely utilized in drug discovery and thus spawned the biotechnology 
industry and the modern age of drug discovery. Modern drug discovery utilizes three main 
methods for discovering new therapeutic agents. These include combinatorial chemistry, high 
throughput screening (HTS), and structure-based or targeted therapies that can be developed and 
virtually screened in silico.  
The use of combinatorial chemistry was first described by Arpad Furka in 1982 with the 
description of the split-mix method4. In this method, all theoretical structural variations in a 
family of compounds are produced in equimolar quantities to form a compound library through 
dividing the solid support bead into equal portions and then coupling each bead with one of the 
structural variations. These portions are then mixed together and comprise one cycle. This is then 
repeated until the desired length of family of compounds is reached. In most applications, the 20 
proteinogenic amino acids serve as the building blocks used to form a compound library. The 
functionality of designing such a library allows for large scale chemical screening to a specific 
drug target as each compound is formed on a single bead and the number of compounds formed 
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increases exponentially with each additional reaction step. Furka’s pioneer work was followed 
by Geysen, Meloen, and Barteling in 1984 who published a method for the rapid synthesis of 
hundreds of peptides that were conjugated to solid supports and used to probe for viral antigen 
epitopes5. Their method relied on parallel synthesis of peptides on polyethylene rods instead of 
the split-mix method. Both methods are still used today as well as more sophisticated variations 
such as dynamic combinatorial chemistry which allow for thermodynamically reversible 
reactions. Combinatorial chemistry was predated by solid phase chemical synthesis developed by 
Robert Bruce Merrifield in 1963, where a compound would be bound to a resin bead and then 
synthesized in a step-by-step method6. Before combinational chemistry, it would take chemists 
several weeks to synthesize a single compound, whereas today, thousands of compounds can be 
synthesized and screened within a single week. Despite the ability to synthesize and screen a vast 
number of compounds in a relatively short time frame, combinatorial chemistry has only 
produced one FDA approved drug to date, that being Sorafenib, a multi-kinase inhibitor to treat 
renal cell and hepatocellular carcinomas7. It has been suggested that the lack of translation of 
combinatorial chemistry derived drugs to the clinic is a result of the lack of chemical diversity 
that is observed in natural products. A statistical analysis performed by Feher and Schmidt 
comparing natural products, drug molecules, and combinatorial chemistry libraries showed that 
combinatorial molecules tend to have a higher molecular weight, fewer chiral centers and 
rotatable bonds, three times as many nitrogen molecules and two fold less oxygen atoms when 
compared to natural products and drug molecules8. From these data it is postulated that 
combinatorial molecules may have a lower binding affinity to a specific target as well as limited 
absorption, distribution, metabolism, and elimination (ADME) when compared to a natural 
product that is smaller in weight, more flexible, and has a higher proportion of electron acceptor 
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and donor molecules to aid in ADME. These observations do not mean that combinatorial 
chemistry has no relevance in drug discovery, but rather it will have to evolve past synthetic 
feasibility and mimic the chemical diversity seen in nature. 
HTS is the second major method scientists use in modern drug discovery. HTS is not a 
single method, but rather an umbrella term to describe the large scale screening of thousands of 
compounds to a drug target using a specific assay within a short time period. The efficiency of 
HTS is the result of robotics and automated systems that can add samples and reagents in a 
controlled, repeatable manner. HTS also utilizes sophisticated computer programs and software 
to analyze the vast amount of data that is generated by these automated systems9. HTS has 
gained popularity over the past decade with many pharmaceutical companies as a result of the 
increasing costs from clinical trials and the high failure rate of many leads. In fact it has been 
estimated that it takes over 12 years for every new drug brought to market and costs 
approximately $800 million. This is due to the fact that only ten out of one million compounds 
enter clinical trials of which only one gets FDA approval10. Therefore, it is paramount that 
pharmaceutical companies utilize efficient and cost effective strategies to identify new 
pharmaceuticals.  
The HTS format utilizes large chemical libraries, including those derived from 
combinatorial chemistry in a microtiter plate. Traditional HTS relied on 96-well microplates, 
however with the advance in technology, it is now possible to use 384 and 1536-well microplates 
and screen up to 500,000 compounds in one week11-13. In addition to the large chemical libraries 
that are needed for HTS, the assay to be used in the screening process is of equal importance. For 
many HTS processes, a drug target is identified and then an assay will be developed around that 
target. These assays tend to be cell-free and detect interactions among small molecules, peptides, 
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or nucleic acids to a target protein. The primary assays used in these cell-free assays are the 
enzyme-linked immunosorbant assay (ELISA) and fluorescence polarization (FP)12.  The 
principle of the ELISA involves the detection of an analyte via an antibody that is linked with an 
enzyme that can interact with its cognate substrate and produce a detectable signal, usually a 
color change in the substrate liquid. This method can be performed directly or indirectly through 
different variations such as a sandwich or competition assay. In the context of drug discovery 
ELISA assays are routinely used to detect an interaction between a chemical compound and a 
drug target. Much like the ELISA, FP is also used to detect binding of an analyte to a drug target. 
With FP, a fluorescent dye is usually conjugated to an analyte and then incubated at different 
concentrations with the drug target. The sample is then excited with plane polarized light and 
spectra are read by a microplate reader. If there is a binding interaction between the two 
molecules, the fluorophore will not be able to rotate freely, and this will result in a shift in the 
absorption spectra. By performing titrations, it is possible to obtain kinetic binding data from FP 
which are useful for drug screening and hit validation. While cell-free assays are important in 
HTS, they tend to be used as a primary screen to identify a hit. Once a hit is identified, a 
secondary screen is performed which may be more biologically relevant such as a cell-based 
assay.  
Cell-based assays are developed to test a drug effect on a specific endpoint. The main 
endpoints used in cell-based HTS are cytotoxicity, cell proliferation, reporter gene or second 
messenger, or cell migration as these tend to be involved in various diseases12,14. Immortalized 
and cancer cell lines are frequently used in cell-based assays given that they are inexpensive to 
culture, have the capacity to replicate an infinite number of times, and represent the disease that 
is being studied. However, cancer cell lines frequently contain gene mutations that could affect 
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experimental data depending on the endpoint investigated. Cytotoxicity and cell proliferation 
assays are predominately performed on drugs that target cancer. Cytotoxicity assays utilize 
fluorescent dyes such as rhodamine derivatives that can only enter the cell once the plasma 
membrane is compromised. Cell proliferation assays such as the (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay on the other hand use tetrazolium-based dyes that 
are reduced to formazan by NAD(P)H-dependent oxidoreductase enzymes in living cells. If the 
drug target to be investigated is a cell-surface receptor or regulates gene transcription, the use of 
a reporter gene such as luciferase that is co-expressed with drug target can be transfected into the 
cell line in order to detect if the drug activates a target gene or protein. Additionally, monitoring 
the activation of a signal cascade by a drug can be performed using a fluorescent molecule that 
responds to ion concentrations, pH, or membrane potential.  
Finally, cell migration and chemotaxis assays are also used in HTS. This assay utilizes a 
transwell or Boyden chamber that contains a cell permeable insert that is nested in a 
microplate15. In this method, cells are seeded on the top side of the insert and then allowed to 
grow in media containing drug. Cells that migrated across insert can then be stained and 
quantified. This assay also is used for cancer cells and studies involving metastasis. Once hits 
have been validated through a secondary screen, they are then considered lead molecules. These 
leads may go through further refinement such as structure activity relationship (SAR) studies, in 
vivo animal models and then to clinical trials.  
While HTS has only been in existence for approximately two decades, there have already 
been a number of drugs on the market that were developed using this method. Examples include 
the tyrosine kinase inhibitors Imatinib, Dasatinib, Erlotinib, and Gefitinib, as well as the protease 
inhibitors Sitagliptin and Tipranavir, and the G-protein coupled receptor (GPCR) inhibitors 
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Ambrisentan, Maraviroc, and Tolvaptan11. Given that HTS has proven to be useful in drug 
discovery with a success rate of greater than 60%, it is expected that pharmaceutical companies 
will invest more resources into this process in the upcoming years11,16,17.  
The third method that is used in modern drug discovery utilizes sophisticated software 
programs to virtually screen large chemical libraries that contain millions of compounds such as 
the ZINC database.  Virtual screening comprises compound assembly, scoring, and optimization. 
Virtual screening not only can be used to identify hits in silico to a selected drug target, but also 
to virtually synthesize a compound that may not be in an investigator’s chemical library. The 
first publication referring to virtual screening was published in 1997 and since then has become 
an integral part of modern drug discovery in conjunction with combinatorial chemistry and 
HTS18. As previously mentioned, virtual screening can be divided into two approaches, namely 
ligand-based and structure-based. With respect to ligand-based virtual screening, three-
dimensional chemical structures of known drug-like pharmacophore molecules are used as a 
starting point to which chemists can virtually synthesize a novel compound to a selected drug 
target. It has been estimated that all drugs currently on the market target less than 500 
biomolecules, and many share similar chemical motifs16. Therefore, there is a great interest in 
synthesizing new chemical entities that may target a wider biological base. The advantages of 
this method are that the investigator will not have to go through the expensive and laborious 
methods of synthesizing and testing thousands of compounds that may not show any activity to a 
selected drug target. Furthermore, ligand-based screening may provide a novel chemical 
compound that is not found in large chemical libraries. The main computer programs used for 
pharmacophore searching are Catalyst, Phase, and Unity. These programs are widely used in 
 8 
 
virtual screening and have most recently shown promise in developing a screen for PI3Kα 
inhibitors19-21.  
The second approach of virtual screening utilizes molecular docking, which is a study of 
binding interactions between two molecules. Structure-based screening takes advantage of 
crystal structures of known drug targets obtained from x-ray crystallography or nuclear magnetic 
resonance (NMR) solution structures that are deposited in the Protein Data Bank (PDB) and then 
assesses and scores binding of compounds to target. Much like ligand-based screening, structure-
based screening has an advantage over other traditional screening methods with respect to the 
fact that large chemical libraries can be pre-screened in silico which reduces the cost of 
synthesizing and testing thousands of compounds. There are a number of programs which use 
different methods to assess docking of a ligand to target.  They explore the conformational space 
of ligands to target and then score this set based upon binding affinity. These programs can be 
further broken down by how they characterize ligand conformation during docking. Programs 
such as ICM, Glide, and Affinity optimize the ligand conformation during docking via the Monte 
Carlo approach, as does Gold, Darwin, and Autodock via the Genetic Algorithm19-21. Fred and 
Slide programs use algorithms that optimize conformation before docking and FlexX, Hook, and 
Dock use algorithms that use incremental docking21. While there are a number of compounds in 
clinical trials such as the Hsp90 inhibitor AUY922, the PPARα/γ agonist cevoglitazar, and the 5-
HT6 antagonist PRX-0734, as well as a few FDA approved drugs, namely the anti-retroviral 
protease inhibitors Saquinavir and Indinavir and the fibronection antagonist Aggrastat that were 
developed using structure-based in silico modeling, virtual screening is still in its infancy20-23.  
Many laboratories are using virtual screening to retroactively assess binding kinetics of 
already FDA approved drugs such as the BCR-ABL inhibitors imatinib and dasatinib and more 
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recently a group which screened 13 antipsychotic drugs to known targets24-25.  The potential of 
virtual screening has come into question, primarily due to the lack of a unifying approach. It has 
been estimated that it is almost a ratio of one approach to one application. This is the result of 
differing approaches to drug discovery as well as what is known about a specific target or its 
respective ligands26. Furthermore, virtual screening algorithms rely on a comprehensive 
understanding of the dynamics of protein folding and macromolecular complex formation, which 
are far from complete. This is further compounded by the allosteric effects of a ligand-target 
complex. Most docking algorithms use static protein structures and therefore are inadequate at 
identification of true ligand-target binding dynamics. It has been suggested that going forward, 
newer models should utilize soft docking and softer repulsion forces as well as side-chain 
flexibility of protein backbones21,26. Additionally, thermodynamic considerations must be made 
such as how temperature affects binding as well as the treatment of water molecules that are not 
fixed. 
While the three methods in modern drug discovery have advantages and disadvantages 
and can be utilized independently of each other, researchers are beginning to integrate them into 
their laboratories. This integration and multi-discipline approach will help further drug discovery 
and the advent of novel therapies for a variety of maladies.  
1.2 Cell Death Pathways 
Multi-cellular organisms use three main modes to regulate cell populations and maintain 
cellular homeostasis, namely apoptosis, autophagy, necrosis and to lesser extent mitotic 
catastrophe. Apoptosis has been the most extensively studied cell death pathway, and is 
characterized by the activation of the caspase family of proteases, chromatin condensation, cell 
shrinkage, membrane blebbing, and DNA fragmentation. Autophagy or self-eating is a process 
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which involves the cell degrading its own components under starved or stressed conditions 
through the fusion of autophagosomes with lysosomes. Necrosis has been traditionally 
considered a passive or accidental means of cell death, associated with physical trauma or 
hypoxic conditions. However, more recent studies have demonstrated that a programmed form of 
necrosis can be activated and involves the receptor interaction protein (Rip) kinases Rip1 and 
Rip 3. These kinases form a complex with a number of other proteins and ultimately induce 
mitochondrial fragmentation via the dynamin relation protein 1 (Drp1). Morphologically, 
necrotic cells contain large cytoplasmic vacuoles, cell swelling, breakdown of the plasma 
membrane and rupture of the cellular contents leading to inflammation. Given that many diseases 
including cancer have unbalanced and dysregulated cell death pathways that lead to acquired 
resistance to cell death, researchers have invested considerable effort into understanding and 
targeting these pathways pharmacologically.  
Apoptosis has been the most extensively studied programmed cell death pathway. 
Although it was known for some time that cell loss occurs in vivo, it was not until 1972 when 
Currie et al. fully characterized the morphological features of apoptosis through electron 
microscopy in a variety of healthy and neoplastic human and animal tissues. Their studies 
showed that apoptotic cells contain pyknotic nuclei, cell shrinkage, membrane blebbing, and 
nuclear fragmentation27. Futhermore, they demonstrated that apoptosis could be induced through 
the addition of noxious agents such as exposure to radiation. Also of interest was the observation 
that surrounding cells would engulf apoptotic cell remnants. Since this pivotal finding, apoptosis 
has been shown to be a vital process organisms use in embryonic development as well as tissue 
architecture and homeostasis28. The molecular mechanism of apoptosis was first elucidated in the 
nematode Caenorhabditis elegans (C. elegans). In these pivotal studies, genetic screening of 
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mutants resistant to cell death resulted in the identification of four genes required for cell death, 
namely egl-1, ced-3, ced-4, and ced-929. Loss of function studies demonstrated that egl-1, ced-3, 
and ced-4 resulted in cell survival, whereas mutation of ced-9 resulted in increased cell death. 
Genetic analysis of these genes across species shows a highly conserved sequence with 
homologues found in higher order mammals, including humans. The ced-3 gene was shown to 
encode for a cysteine protease that cleaves proteins at aspartate residues and is homologous to 
the human family of caspases. Similarly, egl-1 is homologous to the mammalian BH3 family of 
pro-apoptotic proteins as well as ced-4 homologous to the mammalian apopotosomal protein 
Apaf-1 and ced-9 homologous to the Bcl-2 anti-apoptotic proteins. Apoptosis in C. elegans is 
initiated by the binding of ced-4 to ced-3, leading to ced-3 activation. Ced-9 binds to ced-4 in 
healthy cells and prevents that activation of ced-3, but egl-1 can trigger apoptosis by binding to 
ced-9, thereby allowing ced-4 to bind to ced-329. This model system has been invaluable in the 
understanding of the apoptotic cell death pathway in invertebrates and has aided in the 
understanding of apoptosis in higher organisms. Much like invertebrates, mammals also utilize a 
caspase-mediated signaling cascade to initiate apoptosis, albeit much more complex. Apoptosis 
in higher order species can be initiated by two pathways, the extrinsic death receptor pathway or 
the intrinsic mitochondrial pathway. The extrinsic pathway is activated by apoptotic ligands 
binding to their cognate receptors, whereas the intrinsic pathway is initiated by intracellular 
signals such as DNA damage, oxidative stress, or cytotoxic chemicals. 
The extrinsic apoptotic cell death pathway is activated following the binding of ligand to 
death receptors of the TNF superfamily, namely the Fas receptor (FasR), tumor necrosis factor 
receptor (TNFR), and the TNF-related apoptotosis-inducing ligand (TRAIL) family. These death 
receptors are type II transmembrane receptors that aggregate as preformed homotrimers through 
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a pre-ligand assembly domain which is essential for ligand binding and the induction of 
apoptosis. The Fas death receptor complex was the first apoptotic cell death pathway to be 
described and has served as a model for the identification of other death-inducing signaling 
complexes (DISC).  Binding of Fas ligand (FasL) to the Fas receptor results in 
homotrimerization and the clustering of cytoplasmic death domains (DD) which is followed by 
receptor endocytosis. The adapter protein Fas associated death domain (FADD) is then recruited 
to the complex via its DD. The cysteine protease caspase-8 is subsequently recruited to the 
complex through its death effector domain (DED). Formation of this complex results in the 
activation and autoproteolytic processing of procaspase-8. In addition to caspase-8, caspase-10 
has been also reported to be recruited to the DISC via its DD and has been suggested to serve as 
a redundant pathway to caspase-8. However, it has been reported that caspase-10 activation 
alone is insufficient to trigger apoptosis30. The activation of these initiator caspases activates a 
caspase cascade in which the executioner caspases, caspase-3, -6, and -7 are activated to induce 
apoptosis (Figure 1). Much like the FasR, the TRAIL receptors DR4 and DR5 activate apoptosis 
through the recruitment of FADD to the DISC and the activation of the initiator caspases-8 and -
10, followed by the activation of the executioner caspase-330-33.  
With respect to TNFR, once ligand is bound, silencer of death domain (SODD) 
dissociates from receptor complexes and TNFR associated death domain (TRADD) is recruited 
and binds to the DD of TNFR. TRADD then serves as a scaffold protein and binds the adapter 
protein TNFR associated factor 2 (TRAF2), which further recruits the inihibitors of apoptosis 
(IAP) family members XIAP, c-IAPI, cIAPI-2, and survivin. Also recruited to this complex is 
Rip1 kinase via its carboxy-terminal DD. This complex has been collectively coined as complex 
I, and has been shown to activate the nuclear factor kappa-light-chain-enhancer of B cells (NF-
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κB) signaling through the association of IκB kinase (IKK), ultimately leading to cell survival. It 
is only when complex I is endocytosed and interacts with FADD and caspase-8 to form complex 
II that apoptosis occurs30,34,35. However, in the presence of proteins which inhibit caspase-8 such 
as cellular FLICE-like inhibitory protein (c-FLIP), Rip1 kinase dimerizes with Rip3 kinase, 
leading to complex III and the activation of the necroptotic pathway35. Therefore, it could be said 
that TNFR complex acts as a molecular hub for multiple cell signaling pathways.  
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Figure 1: The apoptotic cell death pathway. The extrinsic apoptotic pathway is initiated by the 
binding of FasL to the FasR, which results in the recruitment of FADD, caspase-8 and caspase-
10 to form the DISC. Activation of the DISC induces a caspase cascade which results in the 
activation of the executioner caspases, caspase-3, -6, and -7 and apoptotic cell death. In addition, 
caspase-8 can activate the intrinsic cell death pathway by activating the proapoptotic proteins 
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Bid and Bap31, thereby allowing Bax and Bak to dimerize and form the mitochondrial 
permeability transition pore. Formation of this pore allows for the release of cytochrome c, 
Smac/Diablo, AIF, and Endo G from the mitochondria. This results in the formation of the 
apoptosome and the activation of the executioner caspases. Additionally, Endo G and AIF 
translocate to the nucleus and fragment nuclear DNA.  
 
In contrast to the extrinsic pathway which is activated by extracellular stimuli, the 
intrinsic cell death pathway is activated by a variety of intracellular stimuli such as cytotoxic 
agents, radiation and other DNA damaging agents, viral infection, hypoxia, reactive oxygen 
species (ROS), reactive nitrogen species (RNS), calcium flux, and the absence of growth factors 
and cytokines. These stimuli activate mitochondrial outer membrane permeablization (MOMP) 
via the Bcl-2 family members Bax and Bak which bind to the outer mitochondrial membrane, 
oligomerize, and form a pore that allows for the loss of the mitochondrial membrane potential, 
ATP depletion, and the release of the pro-apoptotic proteins cytochrome c, AIF, Endo G, 
Smac/DIABLO,  and HtrA2/Omi. Antagonizing Bak, Bax and the formation of the MOMP are 
the anti-apoptotic proteins of the Bcl-2 family in healthy cells. Activation of the intrinsic 
pathway can occur under deprivation of growth factors or cytokines which has been shown to 
result in the dephosphorylation of the pro-apoptotic protein Bad. Bad activation allows for Bax 
and Bak to oligomerize as well as inhibits the anti-apopototic proteins Bcl-2 and Bcl-xl through 
heterodimerization. Endoplasmic reticulum (ER) stress caused by misfolded proteins leading to 
calcium release, UV radiation, or Anoikis has been reported to activate the pro-apoptotic proteins 
Bim and Bmf, which also antagonize Bcl-2 and Bcl-xl30-33. Exposure of chemotherapeutic and 
DNA intercalating agents results in cell cycle arrest through the activation of the tumor 
suppressor protein p53. The activation of p53 induces the pro-apoptotic proteins Noxa and Puma 
which then activate Bax and MOMP. Additionally, it has been demonstrated that the activation 
of caspase-8 via the extrinsic pathway can cleave the pro-apoptotic protein Bid, which leads to 
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Bax oligomerization and MOMP30-33. Therefore, it can be said that there is crosstalk between the 
two pathways which can result in signal amplification and a positive feedback loop. Release of 
cytochrome c from the mitochondria allows for the activation of the apoptosome by the binding 
of cytochrome c to Apaf-1. This complex then recruits pro-caspase-9, which results in the 
oligomerization and activation of caspase-9 and subsequent cleavage of the executioner caspases, 
caspase-3, -6, and -7. The complex is further activated by inhibiting the interaction of the IAP 
family members with caspase-3 and -9 via binding of Smac/DIABLO as well as proteolytic 
cleavage by HtrA2/Omi. Moreover, the release of AIF and the nuclease Endo G from the 
mitochondria results in chromatin condensation and DNA fragmentation36.   
Activation of the caspases, caspase-3, -6, and -7 initiates the execution phase of apoptosis 
and results in the biochemical and morphological observations seen in apoptotic cells. Targets of 
the executioner caspases include endonucleases which cleave DNA, the cleavage of various 
cytoskeletal proteins such as fodrin, keratin and actin, and nuclear membrane proteins. Once a 
cell has undergone apoptosis, it is engulfed by neighboring cells or macrophages. The targeting 
of apoptotic cells is mediated by the recognition of the phospholipid phosphatidylserine, which is 
normally present on the inner layer of the plasma membrane but switches to the outer layer 
during apoptosis. Other markers of apoptosis that have been observed are the expression of 
Annexin A-I and calreticulin on the cell surface30-33.  
The apoptotic cell death pathway, through its programmed mechanism, has become an 
attractive pathway for researchers to target therapeutically. Diseases such as cancer and chronic 
inflammation that are the result of defects in the apoptotic pathway have been traditionally 
targeted with cytotoxic agents such as doxorubicin, melphalan, dexamethasone, or radiation37. 
However, as the pathophysiology of these diseases are better understood, researchers can 
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develop peptides and small molecule inhibitors which target these defective proteins as well as 
the use of RNA interference to down regulate the expression of anti-apoptotic genes38. The BCR-
ABL inhibitor imatinib, the HER2 inhibitor traztuzumab, the proteasome inhibitor bortezomib, 
and the EGFR kinase inhibitor gefitinib are a few examples of FDA approved drugs that target 
the apoptotic pathway. 
Autophagy is a highly conserved catabolic lysosomal pathway that results in a cell 
degrading and recycling non-essential cellular components in response to starvation, stress, 
changes in cell volume, accumulation of misfolded proteins, ROS production, hormone 
signaling, and exposure to radiation. Additionally, TRAIL has been shown to induce autophagy 
via c-Jun N-terminal kinase (JNK) pathway and therefore can act as a link between the multiple 
cell death pathways30-32. In healthy cells, autophagy functions to provide amino acids and other 
nutrients to cells under starvation, eliminate damaged organelles and misfolded proteins, and aid 
in cellular remodeling during development in conjunction with the ubiquitin proteasome 
pathway. Therefore, the main role of autophagy can be viewed as pro-survival39. However, 
hyperactivation of autophagy can also lead to cell death39-40.   
Three types of autophagy have been described, namely microautophagy, 
macroautophagy, and chaperone-mediated autophagy (CMA), with macroautophagy being the 
best characterized. Morphologically, autophagic cells contain partially condensed chromatin, 
blebbing, and a large number of vacuoles. Much of what is known about autophagy comes from 
studies done in the yeast Saccharomyces cerevisiae (S. cerevisiae)41. In these studies, a family of 
highly conversed autophagy related genes (ATG) were identified to be involved in this process. 
Induction of autophagy and the formation of the autophagosome have four steps: initiation, 
nucleation, elongation, and sealing (Figure 2). These processes have been shown to be regulated 
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by the PI3K/AKT pathway via mammalian target of rapamycin (mTOR), phosphatase and tensin 
homolog (PTEN), and adenosine monophosphate kinase (AMPK), where mTOR is a negative 
regulator of autophagy and PTEN and AMPK are positive regulators42,43. In mammals, the 
initiation of the autophagosome by stimuli such as starvation, oxidative stress, or treatment with 
mTOR inhibitor rapamycin inhibits the PI3K/AKT pathway or activates AMPK and results in 
the complex formation of the Atg1 homologs ULK1/2 with Atg13 and the scaffold protein 
FIP200.  This leads to the formation of a double layered membrane emanating from the ER 
which encapsulates cytoplasmic proteins. This complex then fuses with acidic lysosomes and 
results in the formation of the autolysosome.  Vesicle nucleation of the autophagosome is 
initiated by the formation of the PI3KC3 (Vps34) complex, of which the Atg6 homolog Beclin-1 
is a member. Beclin-1 has been shown to be imperative for the induction of autophagy, as 
knockout studies have correlated with tumor growth and resistance to cell death39,42,43. In these 
studies, small interfering RNA (siRNA) targeting beclin-1 and Atg5 blocked cell death of 
bax/bak null murine embryonic fibroblasts (MEFs) treated with etoposide, therefore implicating 
autophagy as a cell death mechanism when apoptosis is inhibited.  Once this complex is 
activated, phosphatidylinositol 3-phosphate (PI3P) is generated and results in the recruitment of 
other Atg family members such as Atg2 and WIPI-1 that elongate the autophagosomal 
membrane.  The Atg12-Atg5-Atg16 complex is then activated and aids in vesicle sealing, while 
the autophagic marker LC3 (Atg8) is proteolytically cleaved, lipidated, and specifically binds to 
the autophagosome membrane.  Formation of this complex leads to the fusion of the 
autophagosome with a lysosome and the release its content into the lysosome to be degraded by 
acidic hydrolases contained within the autophagolysosome.  
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Figure 2: The formation of autophagic vesicles. Nutrient starvation and subsequent activation 
of AMPK results in the formation of a double membrane structure around proteins or organelles 
to be degraded via the ULK1/2- Beclin1-hVps34-Atg14-Atg9-WIPI complex. Membrane sealing 
and the formation of the early autophagosome is mediated by LC3 lipidation. Maturation and 
fusion of the autophagosome with the lysosome is mediated Rab7, SNARES, ESCRT, DRAM, 
and LAMP-1/2. Upon fusion, the late autolysosome is formed which results in the hydrolytic 
degradation of vesicle contents and the inner membrane.  
 
It has been reported that there is crosstalk between the cell death pathways44.  More 
specifically, the anti-apoptotic proteins Bcl-2 and Bcl-xl have shown to bind to beclin-1 in the 
absence of stress stimuli and therefore prevent the induction of autophagy.  It has also been 
shown that cancer cells have a reduced expression of beclin-1 compared to normal cells, 
therefore suggesting beclin-1 may act as a tumor suppressor protein. These cells were shown to 
be resistant to autophagy and apoptosis, but overexpression of beclin-1 sensitized cells to a 
number of cytotoxic agents. Crosstalk between apoptosis and autophagy has also been 
demonstrated in multiple myeloma (MM) cell lines. In these studies, MM cells treated with the 
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apoptotic drugs doxorubicin and melphalan were shown to activate a beclin-1 mediated pro-
survival autophagic signal. Furthermore, when cells were treated in combination with the 
reduction of expression of beclin-1, an increase in apoptosis was observed. Autophagy is a 
dynamic process and can both facilitate and inhibit apoptosis not only through pathway crosstalk, 
but also by the regulation of pathway substrates. Given that apoptosis relies on sufficient levels 
of ATP to carry out the catalytic enzymatic processing of a number of proteins, autophagy can 
synergize with apoptosis by maintaining high intracellular ATP levels. Hyperactivation of 
autophagy can also lead to increased apoptosis via oxidative stress and depletion of ATP. 
Conversely, autophagy can antagonize apoptosis by the degradation of misfolded proteins that 
contribute to oxidative stress, a known activator of apoptosis, as well as disrupt mitochondrial 
function and ATP production.  Given that cancer cells have been reported to utilize autophagy as 
a means to drug resistance, agents that block autophagy could prove efficacious as therapeutic 
agents used in combination with approved agents. One such agent being investigated is 
chloroquine. Chloroquine has been reported to prevent the acidification of the 
autophagolysosome and therefore antagonize autophagy. Currently, chloroquine is being tested 
with a number of chemotherapeutic agents such as bortezomib in MM and primary lymphoma 
cell lines, bevacizumab in glioblastoma, paclitaxel in breast cancer, and carboplatin in colon 
cancer45.  
Necrosis has been traditionally viewed as an unregulated, passive form of cell death that 
is the result of physical trauma, hypoxia, or exposure to cytotoxic viral or microbial agents. 
Morphologically, necrosis results in cell swelling, vacuolation, breakdown of the plasma 
membrane, and mitochondrial fragmentation in the case of necroptosis. Hallmarks of classical 
necrosis involve metabolic dysfunction, leading to the depletion of cellular ATP and 
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nicotinamide adenine dinucleotide (NAD+) levels through the overactivation of poly ADP-
Ribose polymerase (PARP), mitochondrial dysfunction, Ca+ flux, and the production of ROS.  
However, more recent studies have reported a programmed form of necrotic cell death referred 
to as necroptosis, which is mediated by the kinases Rip1 and Rip 3. Activation of the Rip1/Rip3 
heterodimer leads to the formation of a 2 megadalton (MDa) ripoptosome complex which 
ultimately induces mitochondrial fragmentation via the dynamin relation protein 1 (Drp1)46. 
Additionally, ROS and Ca+ have been reported to activate Drp1 by a Rip1/Rip3 independent 
mechanism.  The molecular mechanisms that mediate necroptosis are similar to those observed 
in apoptosis, namely a receptor mediated extrinsic pathway and an intracellular intrinsic 
pathway. 
The most extensive research on necroptosis comes from studies involving TNF. In 
addition to TNF inducing cell growth and survival via the NF-κB and MAPK pathways as well 
as apoptosis, it has also been reported that TNF can induce necrosis in fibroblast cell lines47,48. 
The death observed was reported to be distinct from apoptosis, as there was cell swelling, intact 
nuclei, and an absence of DNA fragmentation. This observation was further corroborated in a 
number of other cell lines as well as primary cultures. However, the mechanisms underlying 
necrosis have only begun to be understood.   
The first paper to describe programmed necrosis showed that pretreatment of primary 
human T cells with the pan-caspase inhibitor zVAD still resulted in cell death upon the addition 
of FasL49. Furthermore, treatment of the immortalized human T-lymphocyte Jurkat cell line with 
FasL, TNF, or TRAIL induced necrotic cell death. Moreover, it was shown that this form of 
death was mediated by the serine/threonine kinase Rip1, as Rip1 gene knockdown salvaged cells 
from necrosis. The role of Rip1 was further validated by Lin et al. in murine embryonic 
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fibroblasts50. Additionally, they showed that programmed necrosis was initiated by TNF and that 
TRAF2 and FADD were also contained in this complex and contributed to the production of 
ROS in concert with Rip1. It was also shown that ROS plays a pivotal role in TNF mediated 
necrosis, as the ROS scavenger butylated hydroxyanisole blocked cell death. Further studies 
performed in fibroblasts resistant to caspase dependent cell death were subjected to microarray 
analysis and the expression of another Rip family member, Rip3, along with Calpain and Serpin 
were correlated with cell death51. Rip3 was the only protein to be shown to be involved in 
necrotic cell death. Further studies showed that Rip1 overexpression led to apoptosis in Rip3 
depleted cells, but overexpression of Rip3 resulted in increased necrosis regardless of Rip1 
expression51,52. Therefore, Rip3 expression is imperative for TNF mediated necrosis, but not 
Rip1. These data were further corroborated in murine cytomegalovirus (MCMV) infected cells 
deficient in Rip1 and suggests that Rip1 acts upstream of Rip353.  
The Rip family of kinases is comprised of seven members, but only Rip1 and Rip3 have 
been implicated in necrosis. The functions of the other Rip family members remains to be fully 
elucidated, but recently it was reported that Rip2 may play a role in the activation of the NF-κB 
pathway as well as apoptosis54.  All Rip family members share a highly conserved kinase 
domain, but differ in other domains such as the caspase recruitment domain (CARD) in Rip2, 
ankyrin repeats (Ank) in Rip4, 5, 6, and the Ras of complex proteins/C-terminal of Roc 
(Roc/Cor) in Rip6, 7. The necroptotic protein Rip1 is a 671 amino acid protein with a molecular 
weight of 75 kilodalton (kDa). A Rip1 variant also exists, being slightly shorter at 625 amino 
acids and a molecular weight of 70kDa. Rip1 contains an N-terminal kinase domain, a Rip 
homotypic interaction motif (RHIM), and a C-terminal DD. It is autocatalytically activated via 
phosphorylation of amino acids serine 60 and serine 166. Additionally, it has been shown that 
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Rip3 phosphorylates Rip1 at serine 161. Regulation of Rip1 protein expression has been shown 
to be as a result of polyubiquitin at lysine 48 which targets the protein for degradation by the 
proteosome. Additionally, it has been shown that polyubiquitination of lysine 63 activates the 
NF-κB pathway via docking of Tak1, Tab2/3, and Nemo53. Caspase-8 has also been shown to 
cleave Rip1 and therefore inhibits the activation of necroptosis, thus providing another point of 
pathway crosstalk among the cell death pathways54.  Rip3, the other Rip family member involved 
in the necroptotic pathway is a 518 amino acid protein with a molecular weight of 56kDa. Like 
Rip1, Rip3 contains an N-terminal kinase domain and RHIM domain, but lacks a DD. Rip3 is 
activated through autocatalysis at serine 199 and binds to Rip1 upon activation via its RHIM 
domain. Rip3 polyubiquination at lysines 48, 63 by cIAP1/2 targets the protein for degradation 
by the proteasome and has been reported to activate the NF-κB pathway55,56. Much like Rip1, 
Rip3 can also be cleaved by active caspase-8 and inhibit necroptosis57. The regulation of the 
Rip1/Rip3 complex by caspase-8 was further demonstrated in caspase-8 null mice, which were 
embryonic lethal but mice doubly mutant in caspase-8 and Rip3 were viable and showed normal 
development58. However, these mice did exhibit abnormally high levels of peripheral T cells, 
thereby suggesting that caspase-8 contributes to immune cell homeostasis and the Rip1/Rip3 
necroptotic pathway may act as a secondary mechanism to regulate T cell homeostasis58. The 
Rip1/Rip3 complex has also been shown to be regulated by the NAD dependent deacetylase 
Sirt2, which constitutively binds to Rip3 and deactelyates Rip1 at lysine 530 and allowing 
Rip1/Rip3 complex formation59. In addition to Rip1/Rip3 complex interaction with caspase-8, a 
2 MDa ripoptosome complex was identified upon treatment of etoposide in murine mammary 
carcinoma and keratinocyte cell lines46.  
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Study of the ripoptosome revealed that many of the proteins found in complex I of TNF 
mediated apoptosis were also involved in necroptosis, namely TNFR, TRAF2, TRAF5, TRADD, 
FADD, cIAP1, cIAP 2, and cFlip (Figure 3)46 . It was further demonstrated that the loss cIAP 
ubiquitin ligase expression promoted necroptosis. Additional studies of the ripoptosome 
identified the cylindromatosis (CYLD) protein as well as the tumor necrosis factor activation 
inducing protein 3 (TNFAIP3) as Rip1 deubiquinating enzymes that lead to formation of the 
apoptotic DISC comprising TRADD, FADD, caspase-8, caspase-10, and Rip160,61. However, it 
was reported that the caspase-8 inhibitor cFlip can be activated and prevent the cleavage of Rip1 
by active caspase-8. This inhibition of caspase-8 allows for Rip1 and Rip3 to autophosphorylate 
each other, leading to the formation of the Rip1/Rip3 heterodimer.  
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Figure 3: TNF mediated formation of survival, apoptotic, and necrotic pathways. Upon 
TNF activation, TRAF 2/5, TRADD, cIAP 1/2, and Rip1 are recruited to the cytoplasmic tail of 
TNFR. Polyubiquination of Rip1 at lysine 63 activates the cell survival NF-κB pathway via 
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docking of Tak1, Tab2/3, and Nemo. Deubiquination of Rip1 by CYLD promotes the conversion 
of complex I to complex II, leading to the recruitment and activation of caspase-8. Once 
activated, caspase-8 cleaves Rip1 resulted in the formation of the DISC and the induction of 
apoptosis. Inhibition of caspase-8 by cFLIP, allows for the recruitment of Rip3 to form the 
necroptotic complex IIb. Formation of this complex allows for the formation of the Rip1/Rip3 
and the initiation of necroptosis. 
 
Studies of necroptosis in other cell lines revealed a number of TNF analogous pathways 
that can initiate the Rip1/Rip3 complex, among these are the FasR, T cell receptor (TCR), and 
Toll-like receptor (TLR). In addition, a number of adaptor proteins were also found to be present 
in these complexes, namely the deubiquinase FAF with the FasR; Lck, Fyn, Zap70, and PLC 
with the TCR; and Trip, Trap, and Tram with the TLR60. Energy metabolism has long been 
linked to TNF mediated necrosis with the depletion of cellular ATP levels and the 
overproduction of ROS61,62. The DNA repair enzyme PARP has been implicated in necrosis 
since over activation in response to DNA damage can deplete ATP and NAD+ pools. This in turn 
has been shown to activate apoptosis inducing factor (AIF) and lead to DNA fragment and 
further PARP activation, thereby creating a futile positive feedback.  
More recently, it has been shown that activation of the Rip1/Rip3 necrosome complex 
influences mitochondrial energy metabolism60-62. Rip3 has been shown to allosterically activate 
three mitochondrial proteins involved in cellular metabolism, namely glycogen phosphorylase 
(PYGL), glutamate-ammonia ligase (GLUL) and glutamate dehydrogenase 1 (GLUD1).  These 
proteins are involved in the tri-carboxylic acid (TCA) cycle and promote glycogenolysis and 
glutaminolysis, both of which have been shown to generate ROS. Additionally NADPH oxidase 
(NOX1) is recruited to the plasma membrane via Rip1 upon TNF activation and adds an 
additional source of ROS. These events lead to further ROS production, ATP depletion, and Ca+ 
flux result in necrotic cell death. In addition to metabolic mitochondrial dysfunction, it has been 
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reported that mitochondrial fragmentation can accompany necrosis. However, it was not until 
last year when Wang et al. linked Rip1/Rip3 necroptosis with mitochondrial fragmentation 
mediated by the dynamin GTPase family member Drp1 (Figure 4)63,64. In their pivotal studies, 
Wang et al. performed a Rip3 immunoprecipitation assay using the HT29 colon cancer and HeLa 
cell lines upon treatment with TNF, zVAD, and a Smac mimetic followed by mass spectrometry 
analysis to identify proteins associated with Rip363,64. Two proteins, mixed lineage kinase-
domain like protein (MLKL) and phosphoglycerate mutase 5 (PGAM5) were identified in the 
Rip3 binding complex. MLKL belongs to the mixed-lineage kinase (MLK) family of 
serine/threonine kinase of proteins that modulate the activity of the JNK and MAPK family of 
proteins65. MLKL is a 471 amino acid protein with a molecular weight of 54kDa. A second 
isoform of MLKL has been reported and exists as a 263 amino acid protein with a molecular 
weight of 30kDa. However, even though MLKL contains a kinase domain it lacks a phosphate 
binding glycine rich loop and an aspartate residue at position 349, thereby rendering it incapable 
of any catalytic activity. Phosphorylation of MLKL at threonine 357 and serine 358 by Rip3 has 
shown to be critical for the initiation of necrosis64. Mutational analysis of these sites revealed 
that only one was needed to mediate necrosis, while a double mutant protected cells from cell 
death. The obligatory role of MLKL in necroptosis was further demonstrated via siRNA 
targeting of MLKL that attenuated death. These data were corroborated with MLKL knockout 
mice, which were resistant to TNF mediated necroptosis66. Protein binding studies indicate that 
phosphorylation of Rip3 at serine 227 serves as a docking site for MLKL and mutation at this 
site prevented the execution of necroptosis64.  
The second protein identified in the Rip3 immunocomplex by Wang et al. was PGAM563. 
PGAM5 belongs to the PGAM family of phosphatase proteins that are involved in the catalysis 
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of phospho groups on phosphoglycerate and have been shown to be involved in the glycolytic 
pathway67.  PGAM5 exists as two isoforms; a 289 amino acid long form with a molecular weight 
of 32kDa and a 255 amino acid short form with a molecular weight of 28kDa. Validation of 
PGAM5 as a Rip3 substrate was shown by Wang et al. through an in vitro Rip3 kinase assay 
which phosphorylated recombinant PGAM563. SiRNA gene silencing of PGAM5 demonstrated 
that both long (PGAM5L) and short (PGAM5S) forms of the gene are needed to activate 
necroptosis. More specifically, it was shown that the PGAM5L directly binds to the 
Rip1/Rip3/MLKL complex and then associates with PGAM5S on the mitochondrial membrane 
as determined by SDS-soluble lysate fractionation. Further analysis of the fractionated lysate 
identified the dynamin family member Drp1 as also contained in this complex.  
Drp1 belongs to the dynamin superfamily of GTPase proteins involved in the budding of 
vesicles, division of organelles, cytokinesis, and pathogen resistance68. Drp1 is a 736 amino acid 
protein with a molecular weight of 81kDa. There have been six isoforms of Drp1 identified of 
which the functions remain to be fully elucidated. Drp1 contains an N-terminal GTPase domain, 
a pleckstrin-homology (PH) domain, a middle domain, and a C-terminal GTPase effector domain 
(GED). Drp1 dimers and trimers phosphorylated at serine 637 by cyclic AMP dependent protein 
kinase (PKA) inhibit the GTPase activity, rendering the protein inactive as is retained in the 
cytosol. Dephosphorylation at serine 637 by calcineurin or PGAM5 in conjunction with 
phosphorylation at serine 616 by Cyclin B dependent kinase (CDK1) induces Drp1 translocation 
to the mitochondrial membrane where it oligomerizes to form a constrictive ring around the 
mitochondria, resulting in fragmentation.  
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Figure 4: TNF mediated activation of the necroptotic cell death pathway. Activation of 
complex IIb results in the heterodimerization of Rip1 and Rip3. This interaction is mediated 
through the deacetylation of Rip1 by Sirt 2. The Rip1/Rip3 complex then binds to and activates 
MLKL. Activation of MLK leads to the phosphorylation and dimerization of the phosphatases 
PGAM5L and PGAM5S. One target of the PGAM5 heterodimer is the dynamin GTPase 
superfamily member Drp1. Dephosphorylation of Drp1 at serine 637 allows for the protein to 
migrate to the mitochondria and promote mitochondrial fragmentation, which results in necrotic 
cell death. In addition, the Rip1/Rip3 complex can interact with the PYGL, GLUL, GLUD1 
proteins and hyperactivate the TCA cycle. This overactivation leads to the generation of ROS 
and a flux in calcium levels which have been reported to activate Drp1 mediated mitochondrial 
fragmentation independently of the Rip1/Rip3/MLKL/PGAM5 complex. 
 
Additionally, SUMOylation by mitochondrial anchored protein ligase (MAPL) has also been 
reported to activate mitochondrial fragmentation and deSUMOylation by SENP5 stimualtes 
mitochondrial fission during mitosis. Drp1 recruitment to the mitochondrial membrane is the 
result of the Drp1 binding to the mitochondrial receptors Fis1, Mff, MiD 49/5168-71. Opposing 
Drp1 mediated fission is the mitochondrial fusion proteins Mitofusin 1/2 and Opa1. Regulation 
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of Drp1 is mediated by MARCH5 and Parkin ubiquination which target Drp1 for degradation by 
the proteasome68-71. In addition to the Rip1/Rip3/MLKL/PGAM5 complex activation of Drp1, 
Wang et al. demonstrated that Ca+ and ROS are also able to activate PGAM5 and Drp1 through a 
yet to be fully understood mechanism63,64. Therefore, in addition to an extrinsic receptor 
mediated necrotic pathway, there appears to be an intrinsic intracellular necrotic pathway that 
can be activated.  
Pharmacologically, three molecules have recently been developed to block the necrotic 
pathway, namely necrostatin-1, necrosulfonamide, and mitochondrial division inhibitor 1 (mdivi-
1). Necrostatin-1 is a Rip1 inhibitor and was shown to block Rip1/Rip3 complex formation72. 
More specifically, analysis of the crystal structure of Rip1 revealed that necrostatin-1 bound to a 
pocket in the kinase domain, which prevented autophosphorylation and activation73. A number of 
second generation necrostatin compounds has been developed and have also been shown to 
block necrosis, albeit through different mechanisms which remain to be fully understood73. The 
MLKL inhibitor necrosulfonamide, was discovered to inhibit necrosis through a HTS of over 
200,000 compounds. Mechanistically, it was shown that necrosulfonamide binds the N-terminal 
178 amino acids of MLKL and the cysteine 86 residue was shown to be critical for binding as 
mutation at this site abolished binding64. The Drp1 inhibitor mdivi-1 was developed through 
screening over 23,000 compounds using growth based cell assay in yeast74. A secondary screen 
using a GTPase activity assay showed mdivi-1 specificity for Drp1, but was inactive in other 
dynamin family members. Using the ChemNavigator software, it was suggested that an 
unblocked sulfhydryl moiety on the 2-position of the quinazolinone as well as limited rotation 
about the 3-position nitrogen-phenyl bond were critical for mdivi-1 activity. Given that necrosis 
has been implicated in ischemic and neurodegenerative diseases, agents that target the necrotic 
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pathway may be useful in the treatment of these maladies. Currently, there are a number of trials 
being conducted with these necrotic inhibitors in vivo and could potentially be used in the clinic 
one day75,76. 
1.3 Multiple Myeloma 
MM is a malignant cancer that results in the uncontrolled proliferation of plasma cells. 
These myeloma cells home in the bone marrow and secrete M-proteins (monoclonal antibodies) 
that disrupt the microenvironment and cause destruction of bone tissue, thereby leading to 
hypercalcemia, anemia, and renal failure. MM accounts for approximately 10% of hematopoietic 
cancers and 1% of all cancers and primarily affects individuals over the age of 6577,78. The 
median survival time has increased over the past decade to greater than 5 years from the time of 
diagnosis, mainly due to the use of autologous stem cell transplantation (ASCT) and novel 
therapeutic agents77-80. Preceding MM are two asymptomatic plasma cell abnormalities, namely 
gammopathy of unknown significance (MGUS) and smoldering multiple myeloma. MGUS is 
defined as the presence of serum M-protein < 3 g/dL with fewer than 10% monoclonal plasma 
cells in the bone marrow without the presence of organ damage.  It has been reported that MGUS 
precedes MM, with an annual progression rate of 1%81.  Smoldering myeloma is defined as the 
presence of serum protein > 3 g/dL with greater than 10 % monoclonal plasma cells in the bone 
marrow with lack of organ damage, with a 10% annual progression to MM82. Diagnosis of MM 
can be described as either intermedullary or extramedullary.  Intermedullary myeloma is defined 
as MM which can only exist within the confines of the bone marrow microenvironment while 
extramedullary myeloma is defined as MM which can exist outside of the bone marrow 
microenvironment.  
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Numerous structural and genetic abnormalities have been found in MM. In one study, it 
was reported that 42% of MGUS, 63% of smoldering myeloma, and 57% of MM cases were 
hyperdiploid83,84.   The chromosomal translocations t(4;14)(p16;q32) and t(14;16)(q32;q23) have 
also been reported in MM are usually associated with poor prognosis85. Additional genetic 
abnormalities associated with poor prognosis in MM are the deletion of chromosome 13, 
deletions and amplifications in chromosome 1, the deletion of chromosome 17p13 and 
translocation of the proto-oncoprotein Myc85-87.   
In addition to genetic mutations, MM cells differentially express a number of cell surface 
receptors when compared to normal plasma cells.  The cell adhesion molecule syndecan-1 
(CD56), while not expressed in normal plasma cells, has been reported to be expressed over 
70%88.  Another surface protein, CD28 has also been shown to be overexpressed in MM.  In one 
study, CD28+ plasma cells were detected in 19% of MGUS, 41% of 116 MM, and found in all 
MM cell lines studied89.  Overexpression of other adhesion molecules such as β1 integrin has 
been also observed in MM.  
Treatment of MM is focused on decreasing the signs and symptoms of the disease.  While 
treatment has not been shown to be efficacious in asymptomatic myeloma and only requires 
observation, symptomatic disease should be treated immediately. Traditional therapies for MM 
included treatment with DNA alkalating agents such as melphalan and cyclophosphamide, the 
glucocorticoid prednisone, and the immune modulator thalidomide80,90. More recently, the 
suggested standard of care for newly diagnosed patients who are eligible for ASCT include a 
series of 3-5 cycles of lenalidomide-dexamethazone or lenalidomide-bortezomib-dexamethazone 
(RVD) before ASCT is performed, followed by maintenance with lenalidomide until disease 
progression or intolerance occurs90. Newly diagnosed patients who are not eligible for ASCT 
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receive a combination of melphalan-prednisone-bortezomib, melphalan-prednisone-
lenalidomide, bortezomib-dexamethazone, or lenalidomide-dexamethazone.  Relapsed and 
refractory patients, who have not been previously given a proteosome inhibitor such as 
bortezomib or carfilzomib, respond well to one of these treatments in combination with an 
immune modulator (IMiD). While these regimens offer a multitude of treatment options for MM, 
minimal residual disease is thought to lead to the outgrowth of a drug resistant population that 
renders MM incurable, leading to end-stage organ failure and death77-80. Therefore it is 
imperative that novel therapies are developed to treat MM. 
1.4 CAM-DR and the BM microenvironment 
It has been well established that the tumor microenvironment can dictate 
chemotherapeutic resistance in a variety of cancers91. Early studies by Durand and Sutherland 
suggested that cell-cell contact may contribute to drug resistance92,93. In their studies, Durand 
and Sutherland showed that hamster cells grown in spheroids were more resistant to lethal 
radiation when compared to individual isolated cells. The concept that the tumor 
microenvironment may contribute to drug resistance was further demonstrated by Teicher et al., 
who showed that murine mammary tumors that were made resistant to chemotherapeutic agents 
in vivo, became sensitive to chemotherapeutic agents upon isolation in vitro94. More recent 
mechanistic studies of the bone marrow (BM) microenvironment demonstrated that MM cells 
can bind extracellular matrix (ECM) components such as fibronectin (FN), collagen, laminin, 
hyaluronan, chondroitin and heparin sulfate, and glycosaminoglycans (Figure 5). Damiano, 
Hazlehurst et al. demonstrated that MM cell interaction with the BM microenvironment via 
integrin-mediated cell adhesion to the ECM component FN, led to the activation of signaling 
pathways and modulation of cytokines and growth factor production all of which led to the 
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emergence of de novo drug resistance to the chemotherapeutics agents doxorubicin and 
melphalan via process called cell adhesion-mediated drug resistance (CAM-DR)95.  Since this 
seminal study, the mechanisms associated with integrin-mediated CAM-DR have been resolved 
and involves both the modulation of cell cycle signaling via decreasing levels of p27kip1 and the 
inhibition of cyclin A and E- dependant CDK2 kinase activity96,97. Furthermore, the inhibition of 
drug-induced DNA damage associated with topoisomerase II inhibitors as well as suppression of 
cell death, namely through the downregulation of apoptotic protein Bim and regulating the 
cellular localization of c-FLIPL has also been implicated in mediating CAM-DR. 
Myeloma Cell
Stromal Cell
VCAM
VLA
-4
VLA-4
NCAM
NCAM
Drug resistance{
ECM HA
CD
44
 
Figure 5: Binding of myeloma cells to various ligands confers drug resistance. The binding 
of MM cells to bone marrow stromal cells as well as to fibronectin and hyaluronic acid has been 
shown to protect cells from melphalan and doxorubicin mediated cell death. Mechanistically, it 
has been shown that cell adhesion promotes the upregulation of a number of anti-apoptotic 
proteins such as p27kip1, c-FLIP, Bcl-xl, and p21. In addition, pro-apoptotic proteins such as Bim 
are downregulated upon cell adhesion. Together, these contribute to the CAM-DR phenotype. 
 
 33 
 
Expression levels of peripheral circulating ECM components have been used in MM patients as a 
prognostic indicator of disease status. MM patients present with abnormally high levels of 
plasma FN compared to healthy individuals and at the same time overexpress α4β1 (VLA-4) and 
α5β1 (VLA-5), which can interact with FN and modulate MM cell survival98.  Overexpression of 
laminin and collagen I and IV have also been correlated with poor prognosis in MM99. MM 
patients also present with high levels of hyaluronic acid (HA) and relative levels of circulating 
HA have been shown to have a direct correlation with poor prognosis. Mechanistically, Vincent 
T et al. demonstrated that increased levels of HA induces survival and proliferation in MM cells 
through an IL-6 mediated pathway100.  Moreover, HA anatagonized dexamethasone induced 
apoptosis through an IL-6 dependent mechanism which acted through the downregulation of 
p27kip1 and through a IL-6-independent mechanism involving the up-regulation of Bcl-2 protein 
and NF-κB activation.   
Within the confines of the BM microenvironment, MM cells have been shown to bind to 
a variety of other cell subtypes such as bone marrow stromal cells (BMSC), mesenchymal stem 
cells (MSC), macrophages, osteoblasts, osteoclasts, fibroblasts, endothelial cells, and adipocytes.  
In addition to cell adhesion, soluble factors such as interleukin-6 (IL-6), stromal cell-derived 
factor 1 (SDF-1), and various ECM components that are secreted by BMSCs have also been 
shown to contribute to drug resistance91. Experimental evidence indicates that homing of 
myeloma cells to the bone marrow is predominately driven by SDF-1 and the cell adhesion 
molecules CD44 and VLA-4 integrin101. Nefedova et al. showed that co-culturing of NCI-H929 
and RPMI 8226 MM cell lines with BMSCs caused inhibition of cell death induced by 
mitoxantrone102.  From this study the authors concluded that the resistance offered by co-culture 
was dependent on cell-cell adhesion as well as from soluble factors induced by cell-cell 
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adhesion.  Further work by Shain et al. showed that adhesion of MM cells to FN via β1 integrin 
activated STAT3 via its association with gp130 which led to up regulation of anti-apoptotic 
genes and resulted in cell survival103.  At the same time, adhesion resulted in the secretion of IL-
6 which reversed the G1-S cell cycle arrest associated with FN adhesion thereby resulting in cell 
growth and proliferation. Taken together, these studies suggest that novel therapies that target the 
BM microenvironment in the context of MM would be an efficacious strategy to treat and 
potentially cure a currently incurable disease. 
1.5 Targeting of adhesion molecules and the development of HYD1 
Given that numerous cell adhesion receptors contribute to CAM-DR, strategies that target 
these proteins will prove efficacious in the treatment of cancer. Of all the adhesion molecules 
implicated in CAM-DR, the integrin family of cell adhesion molecules have been the best 
characterized. They are comprised of 18 α subunits and 8 β subunits to form 24 unique 
heterodimers, consisting of an ectodomain, a transmembrane domain, and a short cytoplasmic 
tail.  Integrin variant heterodimer expression is diverse across the lineages104. It has been 
reported that endothelial cells express α6β4 and αVβ5, neural cells express αVβ8, muscles and 
glial cells express α7β1 and hematopoietic cells express α4β1 α5β1105.  Variant expression has 
also been correlated with disease progression such as αVβ1 and αVβ3 in melanoma and 
glioblastoma and VLA-4 and very late antigen 5/ α5β1 (VLA-5) in MM106. The extracellular 
domain binds to the ECM components FN, vitronection (VTN), collagen, and laminin. The 
cytoplasmic tail acts as an adaptor protein for intracellular signaling and links to the 
cytoskeleton, thereby conferring cell-cell and cell-ligand information about the extracellular 
environment via clustering and the formation of focal adhesions. Integrins have been shown to 
be involved in cell growth and proliferation, migration, homing, and tumor progression in 
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cancer. Activation of integrins has been described as bidirectional, meaning that activation can 
be initiated both extracellularly and intracellularly.  Intracellular inside-out signaling through the 
association of adaptor proteins, such as talin, binds to the β subunit cytoplasmic tail and induces 
a conformational change in the ectodomain which increases the affinity of integrins for ligand.  
With respect to extracellular outside-in signalling, binding of ligand induces a conformational 
change which leads to the interaction of the α and β integrin cytoplasmic tails and downstream 
cell signaling. Since integrins lack an intrinsic kinase domain, they recruit kinases through the 
association of adaptor proteins to the cytoplasmic tails.  The adapter protein talin and paxillin 
bind to β-integrin tails and recruit focal adhesion kinase (FAK) and vinculin to the focal 
adhesions. In cells that are FAK null, another analogous protein kinase pyk2, has been shown to 
serve a similar function.  Downstream pathways that have been shown to be activated by 
integrins include PI3K/AKT, MAPK, and JNK. 
A number of therapeutic agents targeting integins are being used in the clinic. The FDA 
approved α4 integrin antibody antagonist natalizumab, is currently approved for the treatment of 
Multiple Sclerosis and Crohn’s disease107,108. Mechanistically, it was shown to prevent integrin 
mediated adhesion of leukocytes to VCAM-1 and MAdCAM-1. Currently, natalizumab is being 
investigated in relapsed/refractory MM patients. Another integrin targeting antibody is the VLA-
5 antagonist Volociximab, which has been reported to inhibit solid tumor growth109. Another 
VLA-5 antagonist being investigated is the small molecule inhibitor JSM6427109. The cyclic 
RGD containing peptide Cilengitide targeting the αVβ3 and αVβ5 integrins is another agent 
being investigated. It recently completed a phase III clinical trial for the treatment of 
glioblastoma and is currently being tested in phase II clinical trials for patients with lung and 
prostate cancer110,111.   
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Another adhesion receptor that has received much attention is the single-pass 
transmembrane glycoprotein receptor CD44. CD44 is comprised of a single gene product which 
is found on chromosome 11p13112. The receptor has an N-terminal ligand binding ectodomain 
containing the Link module; comprised of three intradisulfide bonds, a stalk region containing 
one or multiple variant exons, a transmembrane domain, and a short c-terminal tail which is 
important for cytoskeletal attachment and signal transduction (Figure 6)112. CD44 has a highly 
conserved amino acid sequence among mammalian and avian species sharing between 47-93% 
sequence homology with humans and an almost identical homology in the Link module, 
transmembrane and cytoplasmic tail regions112-113. The CD44 receptor also contains many post-
translational modifications. It has been reported that 25-40% of CD44 molecules are 
phosphorylated at serine 325 and that CD44 is constitutively phosphorylated at this site in 
cultured cells113. While the exact role of serine 325 phosphorylation is unclear, mutations at this 
site have been shown to inhibit HA binding and cell migration as well as modulating the 
interaction of CD44 with the ERM (ezrin, radixin, moesin) family of proteins113,114.  CD44 is 
also palmitoylated at cysteine residues 286 and 295 and while the exact roles these modifications 
play has been yet to be fully understood, it appears that palmitoylation enhances the association 
between CD44 and ankyrin and may also induce clustering of CD44 into membrane 
subdomains113. The CD44 receptor is also highly glycosylated and linked to chondroitin sulfate; 
with at least five conserved N-glycosylation sites in the ectodomain as well as being highly O-
glycosylated in the extracellular region, both of which have been shown to affect ligand binding 
affinity112,115. The predominant ligand for CD44 is the glycosaminoglycan hyaluronic acid (HA); 
however the receptor has also been reported to bind to other ECM components such as 
osteopontin, FN, laminin, collagen, and E-selectin 112,113,116. The crystal structure of HA bound to 
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murine CD44 has been solved and it has been observed that CD44 adopts two conformational 
binding states and this binding is the result of hydrogen binding117. Further studies by Nuclear 
Magnetic Resonance (NMR) and Surface Plasmon Resonance (SPR) have further eludicated the 
two binding configurations of the CD44 receptor, designated as ordered (O) and partial 
disordered (PO)117,118. It has been shown that the binding of HA oligomers at an allosteric site on 
the ectodomain leads to conformational change in the Link module and switches the module 
from the O to PO configuration117-118. Furthermore, while the minimum binding requires an HA 
hexamer, recent studies have demonstrated that there is a positive correlation with the length of 
HA and binding affinity114,118-119. It has long been postulated that this is the result of multiple 
CD44 molecules binding to one HA polysaccharide. This was recently confirmed by Wolny et 
al. using an artificial membrane system in which they demonstrated that multiple CD44 
molecules can bind a single HA polysaccharide through a multivalent nature120.  While the 
crystal structures of CD44 bound to other ligands have yet to be solved, it has been suggested 
that other ligands bind in the ectodomain adjacent to the Link module113,118. The CD44 transcript 
contains twenty exons that give rise to seventeen known isoforms through alternative splicing 
and post-translational modifications. The most ubiquitously expressed isoform is the standard 
form (CD44s), which is comprised of exons 1-5 and 16-20112,113. In addition to the standard 
isoform, there are variant isoforms (CD44v), in which exons 7-15 are incorporated into the stalk 
region of the receptor.  
 38 
 
  
Figure 6: The structure of the glycoprotein adhesion receptor CD44. The receptor consists of 
an extracellular ligand binding domain, a stem region where ten variant exons can be 
incorporated, a transmembrane region, and a short cytoplasmic tail which can bind the adapter 
proteins Ankyrin and ERM family members to link the receptor to the actin cytoskeleton. 
 
CD44v expression has been known to be expressed in certain cell lineages; CD44v8-10 is 
expressed in epithelial cells, CD44v6 expression has been observed in breast, pancreatic, head 
and neck cancers and CD44v4 has been observed in both normal and malignant bladder cell 
lineages113,121-123. CD44 expression is regulated through receptor-mediated endocytosis as well as 
the proteolytic cleavage of the extracellular domain by various matrix metalloproteinases 
(MMPs)113,124. CD44 has been shown to recruit MMP7 and MMP9 to the plasma membrane, 
where in addition to the cleavage of CD44, these proteinases degrade collagen IV as well as 
cleave the inactive precursor forms of transforming growth factor (TGF-β) and heparin-binding 
epidermal growth factor to form functionally active receptors125.  The cleaved transmembrane 
domain of CD44 translocates to the nucleus and activates CD44 gene transcription125,126. While 
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CD44 expression is essential in development, lymphocyte homing and extravasation, and 
maintenance of organ and tissue structure, overexpression of variant isoforms such as v4, v6, and 
v9, have been associated with aggressive cancers121-126. Paradoxically, CD44, depending on the 
cell context, can contribute to either survival or cell death. T-cells derived from CD44-null mice 
are shown to be resistant to cell death induced by concanavalin A stimulation and T-cell 
receptor-induced cell death127,128.  These data indicate that CD44 may be required for depletion 
of activated T-cells.  More recently, Ruffell and Johnson showed that activation of CD44 
expressing Jurkat T-cells with PMA sensitized these cells to HA-induced cell death129.  Of note, 
cell death was independent of activation of caspase 8; and could not be blocked by treatment 
with the pan-caspase inhibitor z-VAD-fmk. CD44 activation through ligand binding has been 
shown to have diverse cellular effects. CD44s activation has been shown to activate apoptosis in 
Jurkat cell lines, whereas CD44v induction has been suggested to do the converse via 
sequestering the FasR130.  Like many other adhesion molecules, CD44 has no intrinsic kinase 
activity; however it gains access to kinases such as FAK, protein kinase C (PKC), and 
phosphatidylinositol 3-kinase PI3K through adaptor proteins such as the ERM family 131,132. In 
addition to CD44 gaining access to kinases through adapter proteins, it has been reported that 
CD44 can also gain access to other signaling complexes through association with other adhesion 
receptors, most notably α4 integrin in lymphocyte extravasation as well as cell growth and 
proliferation signaling through the human epidermal growth factor receptor 2 (HER2), c-Met, 
and vascular endothelial growth factor (VEGF)131-134. CD44 null mice exhibit normal 
development, however the mice are resistant to T-cell activation-induced cell death (AICD)135. 
Furthermore, these mice had an enhanced inflammatory response when presented with a 
challenge and the compensatory up-regulation of the RHAMM receptor led to joint 
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inflammation135-136. Given the diverse nature and its high degree of expression in various 
diseases, CD44 thus appears to be an attractive receptor to study and target therapeutically. More 
specifically, CD44v9+10- was found to correlate with a poor prognosis in MM patients, while 
CD44v9+10+ was associated with stable disease status in MM patients137. Furthermore, CD44 has 
been correlated with drug resistance in MM as well as breast and lung cancer138. In one study, 
MM cells bound to HA coated plates demonstrated resistance to dexamethasone but this 
resistance was reversed when binding was disrupted with anti-CD44 monoclonal antibody138.  
Recently, several in vitro studies targeting CD44 with monoclonal antibodies alone and 
in combination with low molecular weight HA has been shown to induce apoptosis in myeloid 
cells as well as a novel caspase independent pathway in erythroleukemia cells139-142. More 
specifically, one study was able to eradicate human acute myeloid stem cells in non-diabetic 
severe combined immune-deficient (SCID) mice by targeting CD44 receptor with a CD44 
monoclonal antibody that recognized all isoforms142. There has also been an interest in targeting 
CD44 via peptidomimetics. In one report, a group using a CD44v6 derived peptide have 
indicated a role of CD44 in VEGF signaling and angiogenesis143.  A second peptide referred to 
as A6 (acetyl-KPSSPPEE-amino), has been shown to activate CD44 and inhibit migration and 
metastasis in CD44 expressing cells144. Furthermore, this peptide has shown promise in phase I 
and phase II clinical trials in patients with ovarian cancer. Another molecule that has shown 
promise in early stage clinical trials is the immunoconjugate bivatuzumab, a human anti-CD44v6 
monoclonal antibody coupled to a benzoansamacrolide moiety, which has been tested in head 
and neck squamous cell carcinomas145. While these molecules have shown promise in the clinic, 
targeting CD44 will remain a difficult task until the diverse expression and signaling of the many 
CD44 isoforms is more fully understood in both healthy and diseased cell lineages. 
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 Using peptidomimetics, Cress et al. developed six D-amino acid peptides that were 
screened for their ability to adhere to human prostate tumor cells, support tumor cell adhesion, 
and inhibit tumor cell adhesion to ECM proteins146. Using a one-bead one-compound 
combinatorial chemistry approach, Cress et al. identified the D-amino acid peptide HYD1 
(kikmviswkg), to be biologically active and inhibit tumor cell adhesion to immobilized ECM 
proteins146. In addition, an inactive scrambled D-amino acid peptide HYDS (wiksmkivkg) was 
synthesized and used as a negative control. Furthermore, both peptides were tested on their 
ability to be able to inhibit tumor cell motility on laminin-5.  HYD1 was reported to block 
migration of the highly expressed α6 integrin DU145 prostate cancer cell line on laminin-5, 
while HYDS was unable to block migration147,148. Additionally, HYD1 was shown to inhibit cell 
adhesion to laminin-5 at a comparable level as α3, α6, and β1 integrin blocking antibodies.  
Moreover, Cress et al. demonstrated that HYD1 interacted with the α6 and α3 integrin subunits 
while HYDS did not interact with the integrins tested.  In addition, HYD1 was shown to interact 
with the β1 integrin subunit, as depletion of β1 integrin DU145 cells resulted in the inability of 
HYD1 to bind to cell lysates.  From a cell signaling standpoint, HYD1 was shown to activate 
FAK as well as MEK, and ERK in DU145 cells.  HYD1 was also shown to induce cortactin 
mediated cytoskeletal reorganization, with an increase in filamentous actin and an accumulation 
of actin at the plasma membrane. More recently, it was shown through alanine scanning analysis 
and a peptide deletion strategy that the minimal HYD1 sequence required for cell adhesion, 
inhibition of migration, and activation of ERK signaling were kmvixw, xkmviswxx and 
ikmviswxx respectively149.  
 Given that integrins have been implicated in CAM-DR, our laboratory previously utilized 
HYD1 as a molecular tool to delineate mechanistically how cell adhesion contributes to drug 
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resistance in MM150. In this study, it was shown that HYD1, but not HYDS blocked α4β1 
mediated adhesion to fibronectin in the NCI-H929 MM cell line. In addition, HYD1 was shown 
to restore sensitivity to melphalan specific cell death in the NCI-H929/HS-5 bone marrow 
stromal cell co-culture model. However, HYD1 was shown to induce cell death as a single agent 
in three different myeloma cell lines, a result that was not anticipated.  Due to this observation, 
our laboratory proceeded to investigate how HYD1 was exerting its anti-tumor activity. It was 
shown that HYD1 did not induce caspase cleavage and treatment with the pan-caspase inhibitor 
zVAD failed to protect MM cells from death, thereby suggesting that HYD1 induced cell death 
was caspase independent. Additional studies showed that HYD1 did not correlate with other 
markers of apoptotic cell death, namely DNA fragmentation, release of Endo G and AIF from 
the mitochondria, or the activation of the pro-apoptotic protein Bax. Next, electron microscopy 
was performed on HYD1 treated cells and the presence of large double membrane autophagic 
vesicles suggested that the cells may be undergoing autophagy. HYD1 induced autophagy was 
further confirmed by the presence of acidic vesicles through cell staining as well as the 
conversion of LC3-I to LC3-II upon HYD1 treatment in MM cells. Next, HYD1 treatment in 
MM cells that had siRNA targeting the autophagic protein Beclin-1 resulted in an increase in cell 
death, suggesting that HYD1 induced autophagy was a survival signal rather than a cell death 
signal. This data was corroborated by pretreating MM cells with 3-methyladenine (3-MA) before 
HYD1 treatment, which again resulted in an increase in cell death compared to control. 
Moreover, it was shown that HYD1 induced the hallmarks of necrosis, namely mitochondrial 
membrane depolarization, ATP depletion, and the generation of ROS. Of interest was the 
addition of the free radical scavenger N-acetyl-L-cysteine (NAC) in the presence of HYD1 was 
cytoprotective, but did not salvage ATP pools. Lastly, it was shown the HYD1 lacked activity in 
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normal hematopeotic cells and demonstrated modest activity in the in vivo SCID-hu myeloma 
mouse model. 
 More recently, our laboratory sought to further delineate the mechanisms which confer 
sensitivity to HYD1 in MM151. Using a MM cell line referred to as H929-60 that was selected for 
HYD1 resistance, it was shown by FACS analysis as well as by Western blot that the reduction 
in expression of α4 integrin correlated with resistance. Of interest was the observation that the 
expression of the cleaved isoform of α4 integrin was reduced in the H929-60 cell when 
compared to the parental cell line. These data were further corroborated using biotinylated 
HYD1 as bait. This reduction in expression was also shown to result in diminished binding of the 
resistant cell line to FN. Reduction in expression also correlated with a decrease in binding of 
HYD1 at the cell surface as determined by confocal microscopy using 5(6)-FAM conjugated 
HYD1. Furthermore, this reduction in binding resulted in restoring sensitivity to melphalan and 
bortezomib in the HS-5 bone marrow stromal cell co-culture model. Moreover, reduction of α4 
and β1 integrins via shRNA provided partial, but not complete protection against HYD1. Lastly, 
HYD1 was shown to be more potent in myeloma cells from relapsed patients as compared to 
newly diagnosed patients and response was also shown to be correlated with α4 integrin 
expression. Taken together, these data bolster the rationale for the continued preclinical 
development of HYD1. 
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Chapter 2: Objectives 
 
Multiple Myeloma (MM) is a malignant cancer that results in the uncontrolled 
proliferation of plasma cells that accumulate in the bone marrow, thereby leading to bone lesions 
and disruption of the bone marrow microenvironment. While there are a multitude of treatments 
for MM, minimal residual disease is thought to lead to the outgrowth of a drug resistant 
population that renders MM incurable. Therefore, it is imperative that novel therapies that target 
MM are developed. Our laboratory has previously shown that treatment with the novel d-amino 
acid peptide HYD1 (kikmviswkg) induces necrotic cell death in MM cell lines. Importantly, this 
novel peptide and similar compounds demonstrated increased activity in specimens obtained 
from relapsed patients. Due to the intriguing biological activity of our linear peptide, we pursued 
strategies for increasing the therapeutic potential of this class of compounds.  These efforts have 
led to a development of a number of cyclized peptidomimetics. Through alanine scanning 
substitution and in vitro structure activity relationship (SAR) studies, a potent cyclic analog 
referred to as MTI-101, was identified and used for all subsequent studies. Mechanistically, we 
have implicated the adhesion receptor VLA-4 as being involved in HYD1 induced cell death via 
shRNA silencing strategies. However, reducing α4 integrin expression only demonstrated partial 
protection, indicating that other components of the HYD1 binding complex may be required for 
cell death. Thus, in the present study, we investigated the possible role of other adhesion 
molecules and/or complexes that may contribute to HYD1-induced cell death. In preliminary 
studies using an unbiased approach, we performed a total membrane binding assay with biotin 
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conjugated HYD1 and NeutrAvidin beads on NCI-H929 MM cells. Samples were then loaded on 
an SDS-PAGE gel and analyzed by Mass Spectrometry. Data were then mined with the Scaffold 
3 proteome software to determine pertinent hits. The adhesion receptor CD44 was one of the top 
protein hits identified and was confirmed as a valid hit via Western Blot analysis. After analysis 
of our preliminary data the following hypothesis was proposed:  
MTI-101 is mechanistically similar to the linear parental HYD1 peptide and induces 
necrotic cell death by binding to CD44.  
In order to support or refute our hypothesis, the following aims were developed. 
1. Determine if MTI-101 induces necrotic cell death through a similar mechanism to HYD1. 
2. Determine if CD44 is a direct binding partner of MTI-101 and is involved in inducing 
necrotic cell death. 
3. Further delineate the necrotic cell death pathway that is being activated upon MTI-101 
treatment. 
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Chapter 3: Materials and Methods 
 
Cell culture 
NCI-H929, U266, and 8226 cell lines were purchased from ATCC (Manassas, VA) and 
maintained at 37°C and 5% CO2.  Cells were cultured in RPMI-1640 media (GIBCO, Life 
Technologies Carlsbad, CA) and supplemented with 10% fetal bovine serum (GIBCO). For NCI-
H929 cells, 0.05 mM 2-mercaptoethanol was added to culture media. 293FT cells were 
purchased from Invitrogen (Carlsbad, CA) and grown in Iscove’s Dulbecco’s modified Eagle’s 
medium (Cellgro, Manassas, VA) and supplemented with 10% fetal bovine serum (GIBCO).Our 
cell lines are mycoplasm negative and kappa and lambda immunoglobulin expression levels are 
routinely determined.  Myeloma cell lines were tested for secretion of Kappa (H929) or Lambda 
(RPMI-8226 and U266) levels by ELISA and mycoplasm every 6 months 
Peptides, reagents, and antibodies  
HYD1, biotin-HYD1, and 5(6)-FAM-HYD1 were synthesized by Bachem (San Diego, Ca). 
MTI-101, MTI-101 analogues, biotin-MTI-101, and 5(6)-FAM-MTI-101 were synthesized by 
Drs. McLaughlin and Jain. The purified MTI-101 was analyzed using similar analytical HPLC 
conditions and found to have >95% purity. Biotinylated MTI-101 peptide was synthesized on 
Rink amide resin using Fmoc solid phase peptide synthesis strategy. The linear peptide was 
synthesized by first attaching the γ-side chain carboxyl group of Fmoc-Asp-OAllyl to 
trifunctional linker on the resin. The linear peptide was then cyclized on resin, followed by 
attachment of biotin to 6-amino hexanoic acid on the trifunctional linker to give protected 
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biotinylated cyclic peptide MTI-101. Biotinylated MTI-101 was then subsequently cleaved from 
the resin using TFA/TIS/H2O (95:2.5:2.5). The crude peptide was then lyophilized and purified 
by reverse phase column chromatography to greater than 94% purity. A similar method was 
utilized in the synthesis of 5(6)-FAM-MTI-101. TO-PRO-3 iodide and CellROX Green Reagent 
were purchased from Invitrogen. Mdivi-1 and tert-butyl hydroperoxide were purchased from 
Sigma Aldrich (St. Louis, MO). Recombinant soluble Killer Trail was purchased from Alexis 
Biosciences (San Jose, CA). Anti-CD44 (clone 156-3C11), anti-GAPDH (clone 14C10), anti-
RIP1, anti-pDrp1 (Ser637), anti-Drp1 (clone D6C7), anti-pERK (T202/Y204), anti-Erk1/2, and 
anti-Basigin were purchased from Cell Signaling Technology (Danvers, MA). The anti-Rip3 and 
anti-Syndecan-1 were purchased from Abcam (Cambridge, MA), and the anti-Pyk2/Cak β was 
purchased from BD Pharmigen (Franklin Lakes, NJ). The anti-IgG2a mouse was purchased from 
BD Biosciences (San Jose, CA), anti-mouse immunoglobulin/FITC goat F(ab’)2 was purchased 
from Dako (Carpinteria, CA), and anti-rabbit HRP-conjugated and anti-mouse HRP-conjugated 
were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). 
Peptide truncation assay 
In order to determine the minimal peptide sequence needed for bioactivity, truncated HYD1-
derived peptides were synthesized by Dr. Ted Gauthier at the USF Chemistry Core Facility. 
NCI-H929 cells were plated at a density of 4 x 105 cells/ml and treated with 50ug/ml peptide for 
24 hours. Cells were then washed with PBS and incubated with 2nmol/L TO-PRO-3 iodide and 
immediately analyzed for fluorescence intensity using the FACSCalibur flow cytometer (BD 
Biosciences). 
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Structure Activity Relationship (SAR) assay 
In order to develop a more potent analog of HYD1, Drs. McLaughlin and Jain inserted the 
minimal sequence MVISW into a beta-turn promoter scaffold backbone that was developed in 
their laboratory. Using this as a starting point, a series of alanine substitutions were inserted into 
the core sequence and peptides were then subjected to an in vitro cell-based screen. For 
screening, NCI-H929 cells were plated at a density of 4 x 105 cells/ml and treated with varying 
concentrations of peptide for 24 hours. Cells were then washed with PBS and incubated with 
2nmol/L TO-PRO-3 iodide and immediately analyzed for fluorescence intensity using the 
FACSCalibur flow cytometer (BD Biosciences). IC50 values were calculated by log 
transformation of the data and linear regressions derived from the linear portion of the survival 
curves. Additionally, the Langmuir-Hill equation was used as a secondary method to determine 
IC50 values. 
Cell death analysis 
Cells were plated at a density of 4 x 105 cells/ml and treated with varying concentrations of 
peptide for 24 hours. Cells were then washed with PBS and incubated with 2nmol/L TO-PRO-3 
iodide and immediately analyzed for fluorescence intensity using the FACSCalibur flow 
cytometer (BD Biosciences). 
Cleaved caspase-3 activity assay 
Treated and control NCI-H929 and U266 cells were plated at a density of 4 x 105 cells/mL 
before being assessed for cleaved caspase-3 levels using the caspase-3 active form mAb FITC kit 
(BD Pharmigen), as per the manufacturer’s instructions. Samples were analyzed using the 
FACScan flow cytometer (BD Biosciences). 
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Measurement of cellular ATP 
NCI-H929 and U226 cells were treated (400,000 cells/mL) for 1 hour at 5 and 10 µM, 
respectively. Live and dead cells were then counted and subsequently lysed in TAE buffer 
containing 50 µL of 1% TCA.  Cells were lysed by 3 snap freeze-thaw cycles and then 
resuspended in 450 µL of TAE buffer. The lysate was centrifuged at 2000 x g for 15 minutes, 
and supernatant was transferred to Eppendorf tubes.  ATP was measured immediately using the 
ENLITEN ATP assay kit (Promega, Madison WI), and bioluminescence was measured and 
normalized to cell number.   
Measurement of cellular ROS 
NCI-H929 and U266 cells were with 5uM and 10uM of MTI-101 respectively for one hour. 
Cells were then incubated with 5uM CellRox Green dye (Molecular Probes) for 30 minutes, 
washed with cold PBS and immediately analyzed using the FACScan flow cytometer (BD 
Biosciences). Tert-butyl hydroperoxide (TBHP) was used as a positive control. 
Biotin-HYD1 complex capture from total membrane lysate 
1.2 x 108 NCI-H929 or U266 cells were incubated for 30 minutes on ice in AP buffer (25mm 
HEPES pH 8.0, 100mM KCl, 1mM MgCl, 1mM CaCl, 20% glycerol, 1mM PMSF, and 1ug/ml 
leupeptin and aprotinin) and Dounce homogenized. Total cell membrane lysate was obtained 
through centrifugation and quantified by BCA kit (Pierce, Rockford, IL); 500 µg of biotin or 
biotin-HYD1 was incubated with 30 µL of NeutrAvidin beads (Pierce) for 1 hour at room 
temperature, followed by 2 washes in AP buffer. Membrane lysate (300 µg) was added to beads, 
and volume was adjusted to 500 µL and incubated overnight at 4°C. After3 washes in AP buffer 
containing 0.2% NP-40, beads were boiled in Laemmli loading buffer and eluted proteins were 
fractionated by SDS-PAGE.  
 50 
 
LC-MS/MS analysis of biotin-HYD1 binding complex 
Proteins were digested in-gel with trypsin; the resulting proteolytic peptides were analyzed. 
Samples were resolved by SDS-PAGE, trypsin digested, and analyzed by LC-MS/MS and 
identified using Mascot and Sequest searches against human entries in the UniProt databases. 
Scaffold (v.3 Proteome Software,Portland, OR) was used for data mining of proteins identified in 
the biotin-HYD1 binding complex.  
siRNA transfection 
Transfection of NCI-H929 and U266 cells was performed as previously described150. Briefly, 2 x 
106 cells were added to 200 µL of cytomix buffer (in mM: 120 KCl, 0.015 CaCl2, 10 
K2HPO4/KH2PO4, 25 HEPES, 2 EGTA, 5 MgCl2, 2 ATP, 5 gluthathione, and 1.25% DMSO; pH 
7.6). Ten microliters of a 20 µM stock of SMARTpool siRNA directed at Rip1 (Dharmacon, 
Lafayette, CO), Rip3 (IDT, Coralville, IA), Drp1 (Dharmacon), basigin (Dharmacon), syndecan-
1 (Dharmacon) or non-silencing (Dharmacon) was added to the buffer. The mixture was placed 
in a 2-mm cuvette, and electroporation was done at 140V/975 µF. After transfection, cells were 
incubated in the buffer for 15 minutes in a 37°C incubator before being transferred into a 25-mL 
flask containing 10 mL of fresh media. Cells were incubated for 72 hours before treatment with 
MTI-101. For CD44, 20 µL of a 20 µM stock of SMARTpool siRNA (Dharmacon) was used, 
and cells were electroporated a second time at 24 hours to achieve efficient reduction in surface 
expression. 
Recombinant CD44 ELISA binding assay 
NeutrAvidin (Pierce) plates were prepared by adding 100 µL of 50 µg/mL or biotin or biotin-
HYD1 in binding buffer (in mM: 0.5 KCl, 0.3 KH2PO4, 27.6 NaCl, 1,6 Na2HPO4; pH 7.4) for 2 
hours at room temperature.  Full-length recombinant human CD44 (Abnova, Walnut, CA) was 
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then added to the 96-well plates at increasing concentrations and allowed to incubate for 2 
hours in 500 µL of buffer A (25 mM Tris, 150 mM NaCl, 1.0% bovine serum albumin, 0.05% 
Tween 20, pH 7.25%). Bovine serum albumin was added to control for non-specific binding. A 
1:500 dilution of primary CD44 antibody was added to each well and incubated for an 
additional hour, wells were washed, and a 1:10000 dilution (buffer A) of the secondary 
antibody was added to each well for an additional 30 minutes at room temperature.  Wells were 
washed again, and 100 µL of Pico chemiluminescent substrate (Pierce) was added to each well.  
After addition of substrate, plates were read on a Victor chemiluminescence plate reader.   
CD44 overexpression in 8226 cells 
Stable RPMI-8226 cells overexpressing CD44s were generated by infection with retrovirus and 
puromycin selection. Briefly, 293FT cells were grown to 90% confluence in 100-mm Petri 
dishes and then transfected with the pBabe-puro CD44s retroviral vector (Addgene plasmid 
19127) synthesized by the Weinberg lab or a scrambled retroviral CD44 shRNA (Origene, 
Rockville, MD) using the pVPack system (Clontech, Mountain View, CA). RPMI-8226 cells 
were then infected with the retrovirus for 72 hours, and 1 µg/mL puromycin (Invitrogen) was 
added to allow for the selection of a stable population of cells.  
HA cell adhesion assay 
Nunc 96-well microtiter plates were coated with 2mg/ml high-molecular weight hyaluronic acid 
from rooster comb (Sigma-Aldrich). RPMI-8226 vector control and CD44s overexpressing cells 
were plated at a density of 4 x 105 cells/mL and allowed to adhere to plates for 2 hours. Plates 
were washed with PBS and stained with 200ul of crystal violet dye for 20 minutes. Plates were 
then washed with water, air dried, and 200ul of ethanol was added to dissolve crystal violet dye. 
Plates were read by microplate reader at 570nm. 
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5(6)-FAM-HYD1 binding assay in CD44s overexpressing cells 
RPMI-8226 vector control and CD44s overexpressing cells were plated at a density of 4 x 105 
cells/mL and incubated with 6.25 µg/mL 5(6)-FAM or 5(6)-FAM-HYD1 for 15 minutes on ice. 
Cells were then washed 3 times with cold PBS, with fluorescence immediately measured 
(FACScan flow cytometer, BD Biosciences).  
5(6)-FAM-MTI-101 binding assay in CD44 wild-type and knockout mice 
C57BL/6J CD44 wild-type mice and C57BL/6J CD44 knockout mice (SJL.129-Cd44tm1Ugu/J) 
were purchased from the Jackson Laboratory (Bar Harbor, Me). Mice were euthanized in 
accordance with IACUC protocol and whole blood was collected through aortic chest puncture. 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood collected through 
Ficoll separation and red blood cells were lysed. The resulting PBMCs were incubated with 
12.5uM 5(6)-FAM or 5(6)-FAM-MTI-1-1 for 15 minutes on ice. Cells were then washed 3 times 
with cold PBS, with fluorescence immediately measured (FACSCalibur flow cytometer, BD 
Biosciences). 
Immunoprecipitation 
After treatment, cells were washed in cold PBS and lysed on ice with IP buffer (1% Triton X-
100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM EGTA, pH 8.0, 0.2 mM sodium 
orthovanadate, 0.5% IGEPAL CA-630, and protease inhibitor cocktail), and 500 µg of cell lysate 
was pre-cleared with 50 µL A/G beads (Pierce) for 30 minutes before being incubated with 5 µg 
anti-CD44 (156-3C11) or anti-Rip1 overnight at 4°C. After incubation, lysates were incubated 
with 30 µL A/G beads for 1 hour and washed 3 times with IP buffer. Samples were then put in 
2x Laemmli buffer and analyzed by Western blotting. 
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Mitochondrial fragmentation assay 
NCI-H929 and U266 cells were incubated with 20nM Mitotracker Green FM dye and 0.1mg/ml 
propidium iodide (PI) (Molecular Probes) for 20 minutes and then allowed to adhere to 35 mm 
glass bottom microwell dishes (Mattek cultureware, Ashland, MA) pre-coated with Cell-tak (BD 
biosciences) per manufacturer’s instructions. Samples were then treated with MTI-101 and 
immediately observed with a Leica TCS SP5 AOBS laser scanning confocal microscope through 
a 63X/1.4NA Plan Apochromat oil immersion objective lens (Leica Microsystems CMS GmbH, 
Germany).  Argon 488 and HeNe 543 laser lines were applied to excite the samples and tunable 
emissions were used to minimize crosstalk between fluorochromes.  Time Lapse (2 minute 
intervals for 1 hour) and Z stack (60 0.5µm thick slices) images for each sample were captured 
with photomultiplier detectors in resonant scan mode and prepared with the LAS AF software 
version 2.6 (Leica Microsystems, Germany). Maximum projection images of individual cells at 
each time point were analyzed using Definiens® Developer v2.0 (Definiens AG, Munich, 
Germany) software suite.  First, mitochondria fragments were segmented with an autothreshold 
segmentation on the mitotracker stain.  Fragments less than 5 pixels in size were not considered 
in the analysis.  Next, mitochondria fragments were further defined using a watershed 
transformation algorithm.  Finally, the total number of mitochondria fragments per cell was 
normalized by the total area of mitotracker staining within that cell.  
SCID-Hu model  
The SCID-Hu model was performed as previously described150. Briefly, SCID/beige mice 4–6 
weeks old were purchased from Taconic (Germantown, NY). Fetal tissue (18–23 weeks) was 
obtained from Advance Bioscience Resource (Alameda, CA) in compliance with state and 
federal regulations. Two bones were surgically implanted in the mammary fat pad of 6– to 8-
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week female SCID mice. After 6 weeks of bone engraftment 50,000 H929 cells were injected 
directly into the bone and tumor was allowed to engraft for 4 weeks. At 28 days, baseline tumor 
burden was quantified in the sera using a kappa ELISA kit (Bethyl, Montgomery, TX), and mice 
were randomized into treatment groups (10 mice per group). Mice were treated intraperitoneally 
with 8 mg/kg MTI-101 or PBS daily for 21 days. To assess tumor burden as a function of time, 
Kappa levels in the sera were measured weekly. 
5TGM1 Myeloma mouse model 
1x106 5TGM1 cells were injected into 6-8 week old C57BL/KaLwRijHsd mice via tail vein.  At 
day 10, mice were treated with agents at the indicated doses 3 times a week for 3 weeks. All 
drugs were administered intraperitoneally.  IgG2B serum levels were measured by ELISA once a 
week for 4 weeks per the manufacturer’s instructions (Bethyl, Montgomery, TX).   Mice were 
monitored daily for survival with all remaining mice euthanized at day 100.   We found that the 
maximum tolerated dose was 50 mg/kg as we observed early deaths in this cohort (2 out of 10 
animals). 
Statistical analysis 
The statistical analysis of animal survival upon dosing with vehicle control, MTI-101, or 
bortezomib was performed using the Mantel-Cox method. In all other experiments, either a 
student’s t-test or analysis of variance (ANOVA) test was used as indicated by each figure 
legend. The Bonferroni post-hoc test was performed in experiments with multiple comparisons. 
A P-value of ≤0.05 was determined to be statistically significant. 
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Chapter 4: Results 
 
MTI-101 (cyclized HYD1) is more potent in vitro than parent HYD1 compound, is cross 
resistant in the H929-60 cell line and induces caspase-3 independent cell death, ATP 
depletion, and ROS production in NCI-H929 and U266 cells: 
HYD1 was previously shown to induce caspase independent necrotic cell death, ATP depletion, 
mitochondrial membrane potential dysfunction, and reactive oxygen species (ROS) production in 
NCI-H929, U266, and RPMI-8226 cell lines150. In the present study, we took the minimally 
active truncated core region of HYD1 (mvisw) and cyclized that peptide using a beta turn 
promoter scaffold backbone (Fig. 7). The initial sequence inserted was mvvsw which was 
subsequently optimized in the L-configuration. Valine was substituted for alanine as this was 
shown to result in a more potent analog (data not shown). The solubility of mvvsw was very poor 
but the three lysines on the non-recognition strand render MTI-101 water soluble. Alanine 
scanning of the core sequence constrained in the beta turn promoter was used to optimize the 
sequence (Table 1). Substitution of alanine for tryptophan was shown to reduce bioactivity, 
while substitution of alanine for serine as well as nor-leucine for methionine resulted in a more 
active peptide. In this report, the most potent analog (MTI-101), contained the optimized 
sequence NLeVVAW comprised of all L-amino acid peptides within the beta turn promoter 
scaffold backbone and was used for all subsequent studies (Fig. 8).  Survival curves were 
generated comparing HYD1 to MTI-101 in NCI-H929 cell line, with IC50 values of 63.9 µM ± 
6.0 and 8.38 µM± 0.9, respectively using linear regression (Fig 9A). Similar IC50 values of 
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HYD1 and MTI-101 in NCI-H929 were observed using the Langmuir-Hill equation with values 
of 65 µM ± 3.6 and 9.4 µM± 0.9 respectively. We also observed an increase in potency of MTI-
101 when compared to HYD1 in U266 cell line, with IC50 values of 89.03 µM ± 18.6 for HYD1 
and 22.1 µM ± 4.25 for MTI-101 (Fig 9B).  Furthermore, biotin was conjugated to the N-
terminal lysine residue of HYD1 and this chemical probe (biotin-HYD1) was initially validated 
as retaining biological activity in vitro (Fig. 9C). Interestingly, conjugation of biotin to the beta 
turn of MTI-101 resulted in a peptide that exhibited a biphasic survival curve, thus indicating 
either; the peptide binds multiple targets, aggregates at higher concentrations, or biotin 
conjugation may lead to steric hindrance to its cognate receptor. However, this peptide was 
shown to pull-down proteins contained in the biotin-HYD1 complex and thus was used as a 
molecular tool to delineate proteins contained in the binding complex. Further studies are 
warranted to investigate the observed biphasic survival curve of biotin-MTI-101. 
 
Figure 7: Truncation of the HYD1 peptide reveals mvisw as the minimal sequence needed 
to remain bioactive. N- and C- terminal truncated peptides derived from the HYD1 peptide 
were synthesized by the USF chemistry core facility. In order to assess bioactivity, NCI-H929 
cells were incubated with 50ug/ml of each peptide for 24 hours. Cells were then washed, stained 
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with 2nmol/L TO-PRO-3 iodide, and subjected to FACS analysis. Experiments were run in 
triplicate and repeated 3 times.  
 
Table 1: Alanine scan of cyclized active HYD1 core. 
Peptide R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 IC50 SD
PJ 6-78 cyclized l-HYD1 K L K L K W S V V M 15.5 7.7
PJ 6-104 K L K L K A S V V M 57.1 22.5
PJ 6-105A K L K L K W A V V M 4.1 1.9
PJ 6-106 K L K L K W S A V M 19 6.9
PJ 6-107A K L K L K W S V A M 6.2 2.7
PJ 6-108 K L K L K W S V V A 31.1 7.6
PJ 6-109 K L K L K V S W M V 17.6 4.1
PJ 6-110A K L K L K W S V V N* 2.6 1.3  
In an effort to increase the therapeutic potential of the linear peptide, the core sequence mvvsw 
was inserted into a beta turn promoter scaffold backbone developed by Drs. McLaughlin and 
Jain. Valine was substituted for isoleucine as this resulted in a more potent peptide. In order to 
assess bioactivity, NCI-H929 cells were incubated with various concentrations of peptide for 24 
hours. Cells were then washed, stained with 2nmol/L TO-PRO-3 iodide, and subjected to FACS 
analysis. Cell survival curves were generated and IC50 values were calculated via linear 
regression analysis. Replacing alanine for serine and nor-Leucine for methionine resulted in a 
more potent compound compared to parent compound. Experiments were run in triplicate and 
repeated 3 times.  
 
Figure 8: The chemical structure of the most potent HYD1 analog, MTI-101. The initial 
sequence inserted into the beta turn promoter scaffold was mvvsw, which was subsequently 
optimized in the L-configuration. The solubility of mvvsw was very poor but the three lysines on 
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the non-recognition strand render MTI-101 water soluble. The optimized sequence of MTI-101 
containing all L-amino acid peptides within the beta turn promoter scaffold backbone is 
NLeVVAW and used for all subsequent studies. 
 
As with the previous study describing the mechanism of linear HYD1, we were interested in 
delineating the mechanism by which MTI-101 treatment resulted in cell death in myeloma cells. 
When NCI-H929 and U266 cells were treated with 5 and 10 µM MTI-101, respectively, we did 
not detect cleaved caspase-3 (Fig. 10A). Treatment with recombinant soluble Killer Trail was 
used as a positive control. Similar to HYD1, we saw a statistically significant decrease in ATP 
levels in NCI-H929 and U266 cells upon treatment with 5 and 10 µM MTI-101 (Fig. 10B). 
Furthermore, treatment with MTI-101 resulted in a statistically significant increase of ROS 
production (Fig. 10C). Additionally, we observed that the acquired HYD1 resistant cell line 
H929-60 that was developed in our laboratory was cross resistant to MTI-101 (Fig 10D).  
Taken together, these data suggest that MTI-101 may be mechanistically similar to the linear 
peptide HYD1 as evidenced by disrupted mitochondrial function without activation of caspase-3. 
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Figure 9: MTI-101 is more potent than linear parental HYD1 peptide and retains 
bioactivity upon biotinylation. A direct comparison of HYD1 and MTI-101 was performed in 
NCI-H929 (A) and U266 (B) cells treated for 24hrs and cell death was determined by FACS 
analysis. Cell survival curves were generated and IC50 values were calculated via linear 
regression analysis; 63.9 µM ± 6.0 for HYD1 and 8.38 µM± 0.9 for MTI-101 in NCI-H929 and 
89.03 µM ± 18.6 for HYD1 and 22.1 µM ± 4.25 for MTI-101 in U266. The Langmuir-Hill 
equation was used as a secondary method for IC50 value calculation which was consistent with 
that of linear regression; 65 µM ± 3.6 for HYD1 and 9.4 µM± 0.9 for MTI-101 in NCI-H929. (C) 
In order to capture the peptide binding complex, biotin was added to the N-terminal lysine of 
HYD1 and to the beta turn promoter of MTI-101, both biotinylated complexes remain active and 
induced cell death in NCI-H929 cells, however biotinylation of MTI-101 resulted in a biphasic 
curve which could indicate; multiple binding partners, peptide aggregation, or steric hindrance of 
the biotin molecule for the cognate receptor of MTI-101. Experiments were run in triplicate and 
repeated 3 times.  
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Figure 10: MTI-101 induces caspase-3 independent cell death, ATP depletion, ROS 
production and is cross resistant in the H929-60 cell line. NCI-H929 and U266 cells were 
treated with 5 µM and 10 µM of MTI-101 respectively for 24 hrs and then caspase-3 activity was 
measured (A). The caspase inducer TRAIL was used as a positive control for cleaved caspase-3 
activity.  (B) NCI-H929 and U266 cells were treated for 1 hour with 5µM and 10 µM MTI-101 
and total cellular levels of ATP were measured (RLI= relative luminescence intensity). (C) NCI-
H929 and U266 cells were treated with 5 and 10uM MTI-101 respectively or 0.5% tert-butyl 
hydrogen peroxide as positive control for 1 hour, stained with CellRox Green for 30 minutes and 
washed and FACS analysis was used to determine ROS production (MFI= median fluorescence 
intensity). (D) MTI-101 is cross resistant in the HYD1 acquired resistant H929-60 cell line. NCI-
H929 and H929 cells were treated for 24 hours with 75uM HYD1 and 3uM MTI-101. 
Experiments were run in triplicate and repeated 3 times. Statistical significance was determined 
by ANOVA, *P≤0.05.  
 
CD44 binds to HYD1 and is found in the biotin-HYD1 and biotin-MTI-101 binding 
complex in NCI-H929 and U266 cells: 
Previously, we showed α4-integrin as being part of the HYD1 binding complex151. To this end 
we saw partial, but not complete, protection from HYD1-induced cell death when α4-integrin 
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expression was reduced, thereby indicating other proteins must be involved in cell death. Using 
an unbiased chemical biology approach, we sought to identify the biotin-HYD1 and biotin-MTI-
101 binding complex. Given that our previous study showed HYD1 binding at the cell surface151, 
we isolated total membrane fractions from NCI-H929 and U266 cells and incubated these 
fractions with biotin-HYD1. Complexes were then resolved by SDS-PAGE before LC-MS/MS 
protein identification. These data were then mined using the Scaffold 3 Proteome software, and 
adhesion receptors with their respective number of peptides were identified from the HYD1 
binding complex (Table 2). The glycoprotein receptor CD44 was identified in both myeloma cell 
lines. CD44 is known to associate with α4-integrin and is critical for homing and 
extravasation152.  Further validation of CD44 being present in the biotin-HYD1 and biotin-MTI-
101 binding complex was confirmed using Western blot analysis (Fig. 11). Based on previous 
reports indicating CD44 in both caspase independent and dependent cell death130,139,141,142,153, we 
postulated that CD44 may be the initial binding target of HYD1 and MTI-101 and is required for 
initiating the cell death cascade induced by treatment in myeloma cells. To investigate whether 
CD44 binds directly to HYD1, we coated 96-well NeutrAvidin plates with biotin-HYD1 and 
incubated the plates with full-length recombinant human CD44. We observed a concentration 
dependent increase in binding of recombinant CD44 (Fig. 12). To investigate whether 
overexpression of CD44 in MM cells would increase HYD1 binding, we used the 8226 cell line 
as 8226 cells had the lowest basal level of CD44 among the tested myeloma cell lines (data not 
shown). Retroviral infection of CD44s was used to overexpress CD44 in 8226 cells, and 
expression was confirmed by Western blot (Fig. 13A). A HA adhesion assay was performed to 
confirm that functional CD44s was being expressed (Fig. 13B).  Although we observed an 
increase in binding to HA, this increase was only 2.5 fold whereas expression was increased 
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more drastically.  As shown in Fig. 13C, there was a 1.5 fold increase (P<0.05, ANOVA 
Bonferroni post hoc) of 5(6)-FAM-HYD1 binding in the 8226 CD44s overexpressing cells 
compared to vector only cells. Additionally, we investigated whether overexpression of CD44s 
was sufficient to increase the sensitivity to MTI-101 induced cell death. As shown in (Fig. 13D), 
we did not observe a statistically significant change in cell death between the CD44s-
overexpressing cells and the vector control. Finally, isolating PBMCs from CD44 wild-type and 
knockout mice, we observed a statistically significant decrease in peptide binding in the CD44 
knockout cells when compared to wild-type (Fig. 14). These data indicate that CD44 expression 
correlates with binding of 5(6)-FAM-HYD1and MTI-101 but not cell death.  Moreover, although 
these data indicate that CD44s expression is not rate limiting with respect to cell death, these 
results do not rule out the potential role of  intracellular signaling analogous to an activated T-
cell dictates sensitivity to ligand induced cell death or lateral and downstream signaling 
components such as α4 integrin as being rate limiting for MTI-101-induced cell death.  We are 
currently pursuing the downstream binding partners of CD44 which may be rate limiting for 
mediating MTI-101 induced cell death. 
 
Table 2: Biotin-HYD1 binding complex in NCI-H929 and U266 MM cells.  
 
In order to identify proteins in binding complex, biotin-HYD1 was used as a molecular tool to 
capture binding partners. Membrane lysate (150 µg) was incubated with 500 µg of biotin, biotin-
HYD1, or biotin-MTI-101 bound to NeutrAvidin beads. Beads containing complexes were 
incubated overnight, washed, and proteins separated by SDS-PAGE, trypsin digested, and 
                            NCI-H929                                       U266
Protein ID # unique peptides identified Protein ID # unique peptides identified
CD44 7 Basigin 8
Basigin 7 ICAM1 6
Syndecan-1 5 Syndecan-1 6
NCAM1 4 CD44 5
a4 integrin 3 ICAM3 3
B1 integrin 2 CD59 2
CD59 3
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analyzed by LC-MS/MS. Listed are proteins identified in the biotin-HYD1 binding complex in 
NCI-H929 and U266 cell line using LC-MS/MS. 
 
 
Figure 11: CD44 binds to HYD1 and is affinity purified in the biotin-HYD1 and biotin-
MTI-101 binding complexes from NCI-H929 and U266 cells.  Confirmation by Western blot 
analysis that CD44 was contained in the HYD1 and MTI-101 binding complexes. Membrane 
lysate (150 µg) was incubated with 500 µg of biotin, biotin-HYD1 (A,B), or biotin-MTI-101 
(C,D) bound to NeutrAvidin beads. Beads containing complexes were incubated overnight, 
washed, and proteins separated by SDS-PAGE, and probed for CD44.  Western blots were 
repeated 3 times and a representative blot was shown.  
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Figure 12: HYD1 bind to recombinant CD44. ELISA-based binding assay confirms that 
biotin-HYD1 binds to full length recombinant human CD44 in a concentration-dependent 
manner (RLU= relative luminescence units).  Biotin was bound to NeutrAvidin-coated wells to 
control for non-specific binding. Experiments were run in triplicate and repeated 3 times. 
Statistical significance using ANOVA, *P≤0.05. 
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Figure 13: Overexpression of CD44s in 8226 via retroviral infection results in increased 
HYD1 binding but not cell death.   (A) To assess CD44-HYD1 binding in live cells, the 8226 
MM cell line was used to overexpress CD44s as it had the lowest basal level of CD44 expression 
of MM cells tested. Retroviral transfection of CD44s and puromycin selection in 8226 led to a 
stable CD44s overexpressing cell line. (B) To confirm that functional CD44 was overexpressed 
in 8226 cells, 96-well plates were coated with 2 mg/mL hyaluronic acid (HA) overnight and then 
incubated with 8226 scrambled or 8226 CD44s cells at a density of 4 x 105 cells/mL for 2 hours. 
Plates were washed and stained with crystal violet dye, and absorbances were measured at 540 
nm. (C) Overexpression of CD44s in 8226 MM cells resulted in more binding of fluorescently 
labeled 5(6)-carboxyfluorsecein (FAM) conjugated HYD1. MFI= median fluorescence intensity. 
(D) Overexpression of CD44s did not result in increased sensitivity to MTI-101. Experiments 
were run in triplicate and repeated 3 times. A representative Western blot from 3 independent 
experiments was shown. Statistical significance using ANOVA, *P≤0.05. 
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Figure 14: CD44 KO mice exhibit less binding of MTI-101 compared to WT mice. PBMCs 
isolated from CD44 wild-type and knockout mice were incubated with 12.5uM of 5(6)-
carboxyfluorsecein 5(6)-FAM or the fluorescently 5(6)-carboxyfluorsecein (FAM) conjugated 
5(6)-FAM-MTI-101 for 15 minutes on ice. Cells were then washed 3 times with PBS and 
binding was determined by FACS analysis. Experiments were run in triplicate and repeated 3 
times.  A representative sample is shown above. Statistical significance using ANOVA, *P≤0.05. 
 
Reduction of CD44 cell surface expression results in the activation of cleaved caspase-3 in 
NCI-H929 and U266 cells: 
To further address the role of CD44 in MTI-101-induced cell death in myeloma, we reduced cell 
surface expression targeting of all isoforms of CD44 in NCI-H929 and U266 cell lines. Optimal 
reduction in CD44 expression was achieved 72 hours after siRNA transfection (Fig. 15A and 
15C). Interestingly, we observed that, when CD44 expression was reduced, both cell lines 
appeared to be less viable compared to the non-silencing control cells. To assess which cell death 
pathway was involved in this observation, we used a capase-3 antibody, which only recognizes 
the active form of caspase-3. As shown in Figures 15B and 15D, reduction in cell surface 
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expression of CD44 resulted in a significant increase in cleaved caspase-3 versus that shown in 
non-silencing control cells. These data suggest that CD44 is required for survival in myeloma 
cell lines, validate CD44 as a potential target for the treatment of MM, and indicate that CD44 
may be a key regulator of both ligand induced necrotic cell death and inhibitor of apoptotic cell 
death. To examine other members of the binding complex we reduced the expression of 
syndecan-1 and basigin. Reducing the expression of basigin or syndecan-1 failed to confer 
resistance to MTI-101 induced cell death (Fig. 16 and 17).   
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Figure 15: Reduction in CD44 expression led to cell death, as determined through cleaved 
caspase-3 activation. (A and C) CD44 expression determined by FACS analysis in U266 and 
NCI-H929 MM cells. (B and D)Reduction of CD44 surface expression in U266 and NCI-H929 
MM cells results in the activation of cleaved caspase-3 (NS = non-silencing). Experiments were 
run in triplicate and repeated 3 times. Statistical significance was determined using Student’s t-
test, *P≤0.05. 
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Figure 16: Reduction in syndecan-1 expression failed to confer resistance to MTI-101 
induced cell death. (A and C) Syndecan-1 expression determined by FACS analysis in NCI-
H929 and U266 MM cells. (B and D) Reduction of syndecan-1 surface expression in NCI-H929 
and U266 MM cells failed to confer resistance to 10um and 20uM of MTI-101 after 6 hour 
treatment in NCI-H929 and U266 cells respectively (NS = non-silencing). Representative 
Western blot is shown from 3 independent experiments. Experiments were run in triplicate and 
repeated 3 times. Statistical significance was determined using Student’s t-test, #P≥0.05. 
 
MTI-101 induces CD44-associated agonistic signaling in NCI-H929 and U266 cells: 
CD44 has been shown to associate with focal adhesions and a number of cell signaling 
pathways154-156. Furthermore, we previously showed that HYD1 induces autophagy, which 
protects myeloma cells against death150. To examine whether MTI-101 treatment would 
modulate the interaction between CD44 and its associated proteins, we pretreated NCI-H929 and 
U266 cells with MTI-101 and performed a CD44 immunoprecipitation assay. As shown in 
Figures 18A and 18B, there was an increased association with the focal adhesion tyrosine kinase 
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Figure 17: Reduction in basigin expression failed to confer resistance to MTI-101 induced 
cell death. (A and B) Basigin expression determined by Western blot in NCI-H929 and U266 
MM cells. Reduction of basigin expression in NCI-H929 and U266 MM cells failed to confer 
resistance to 10um and 20uM of MTI-101 after 6 hour treatment in NCI-H929 and U266 cells 
respectively (NS = non-silencing). Representative Western blot is shown from 3 independent 
experiments. Experiments were run in triplicate and repeated 3 times. Statistical significance was 
determined using Student’s t-test, #P≥.05. 
 
protein Pyk2 immediately following MTI-101 treatment in both myeloma cell lines. We also 
observed a transient activation of Erk/Map kinase pathway upon MTI-101 treatment in NCI-
H929 and a more sustained activation in U266 cells (Fig. 18C and 4D). Taken together, these 
data indicate that MTI-101 induces agonistic CD44 associated signaling as evidenced with 
association of CD44 with Pyk2 and activation of the Erk pathway. Furthermore, the activation of 
the Erk pathway and Pyk2 may lead to the rationale design of combination strategies for 
increasing the efficacy of this novel class of compounds. 
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Figure 18: MTI-101 treatment induces transient phospho-Erk1/2 and CD44-associated 
Pyk2 complex in NCI-H929 and U266 MM cells. (A-B) CD44 immunoprecipation was 
performed after MTI-101 treatment in NCI-H929 and U266 cells and probed for Pyk2 and 
CD44. (C-D) NCI-H929 and U266 cells were treated with 5uM and 10uM MTI-101 respectively 
for various time points before whole cell lysis in RIPA buffer and probed for pErk (T202/Y204) 
and tErk. Experiments were repeated 3 times and shown is a representative Western blot. 
 
CD44 co-localizes with proteins associated with necrosis in NCI-H929 and U266 MM cell 
lines: 
Our laboratory previously reported that MM cells treated with HYD1 resulted in necrotic cell 
death150. To this end, it was shown that there was mitochondrial dysfunction, ATP depletion, and 
the generation of ROS. Recently, numerous reports have indicated that cells can initiate an 
apoptotic-like programmed form of necrosis called necroptosis. Critical mediators of necrosis 
include the serine/threonine kinases Rip1 and Rip3 and the GTPase, Drp1. Drp1 is critical driver 
of mitochondria fission and activity of the GTPase is negatively regulated by phosphorylation on 
serine 63761,63.  Interested in determining if CD44 associates with proteins associated with 
necroptosis, we performed immunoprecipitation assays from whole cell lysates treated with 
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MTI-101 at various time points. As shown in figure 19, CD44 was observed to co-localize with 
Rip1 in both NCI-H929 and U266 MM cells. Interestingly, this co-localization was independent 
of MTI-101 and there was no consistent trend in co-localization over treatment time. In an 
attempt to further delineate necroptotic proteins involved in MTI-101 induced cell death, 
analysis of data obtained from LC-MS/MS immunoprecipitation pull-down assays were 
performed. To this end, caspase-8, caspase-10, Drp1, and the c-FLIP analog and caspase-8 
inhibitor TNFAIP8157,158 were found to be contained within the HYD1 binding complex. These 
proteins were further validated as being associated with CD44 via Western blot (Fig 20). 
However, much like Rip1 there was no consistent trend in co-localization with CD44 over 
treatment time. Taken together, these data suggest that the necroptotic pathway may be initiating 
MTI-101 induced necrotic cell death. 
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Figure 19: CD44 co-precipitates with the necroptotic protein Rip1 in MM cell lines. CD44 
immunoprecipation was performed after MTI-101 treatment in NCI-H929 (A) and U266 (B) 
cells and probed for the necroptotic protein Rip1. Conversely, a Rip1 immunoprecipitation was 
performed after 5uM and 10uM of MTI-101 treatment in NCI-H929 (C) and U266 (D) cells and 
probed for CD44. A representative Western blot is shown from 3 independent experiments. 
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Figure 20: CD44 co-precipitates with proteins associated with necroptosis. CD44 
immunoprecipation was performed after 5uM and 10uM of MTI-101 treatment in NCI-H929 (A) 
and U266 (B) cells and probed for the necroptotic complex proteins Drp1, caspase-8, caspase-10, 
and TNFAIP8. A representative Western blot is shown from 3 independent experiments. 
 
Reduction in Rip1, Rip3, and Drp1 expression results in modest increase in survival of 
U266 cells upon MTI-101 treatment: 
In an attempt to determine the role of necroptosis in MTI-101 induced cell death, the reduction 
of expression of Rip1, Rip3, and Drp1 and subsequent treatment with MTI-101 was pursued. To 
this end, using siRNA targeting Rip1, Rip3, or Drp1, we achieved efficient reduction in gene 
expression in U266 cells 72 hours after transfection. Following siRNA transfection cells were 
treated with 10 µM MTI-101 for 6 hours before cell death was quantified via TO-PRO-3 iodide 
staining and FACS analysis. Our results showed a modest, but significant, increase in cell 
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survival upon MTI-101 treatment and reduced expression in each of the respective proteins 
involved in necroptosis in U266 cells (Fig. 21). To investigate pharmacological inhibition of the 
necroptotic pathway, cells were pretreated with 100 µM of the Drp1 inhibitor mdivi-1 for 1 hour 
before treatment with 10 µM MTI-101 for 6 hours, with cell death quantified via TO-PRO-3 
iodide staining and FACS analysis. Our results again showed a modest but significant increase in 
cell survival upon pretreatment with mdivi-1. We also observed a modest decrease in 
phosphorylated Drp1 levels in U266 cells upon MTI-101 treatment (Fig. 22A) suggesting that 
MTI-101 induces activation of Drp1. During necroptosis activation of the phosphatase PGAM5 
is required for de-phosphorylation and subsequent activation of the GTPase Drp1, leading to 
mitochondrial fission and necrosis63,64.  Together, these data indicate that Rip1/Rip3 and Drp1 
dependent necroptosis is partially involved in MTI-101-induced cell death in the U266 myeloma 
cell line. 
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Figure 21: Reduction in Rip1/Rip3 and Drp1 expression results in modest increase in 
survival in U266 MM cell line upon MTI-101 treatment. U266 cells were incubated with 
siRNA targeting Rip1 (A), Rip3 (B), and Drp1 (C) for 72 hours before treatment of 10µM MTI-
101 for 6 hours, with cell death determined by FACS analysis. (A-C) A modest, but statistically 
significant increase in survival was seen. (D) U266 cells were pretreated with 100 µM Mdivi-1 
for 1 hour before treatment with 10 µM MTI-101 for 6 hours, with cell death determined by 
FACS analysis (NS = non-silencing). Representative Western blot is shown from 3 independent 
experiments. Experiments were run in triplicate and repeated 3 times. Statistical significance 
using Student’s t-test, *P≤0.05. 
 
MTI-101 necrotic cell death is Rip1, Rip3, and Drp1 independent in NCI-H929 cells: 
In NCI-H929 cells, we did not observe a statistically significant difference in cell survival upon 
MTI-101 treatment when Rip1, Rip3, or Drp1 expression levels were reduced using siRNA and 
mdivi-1 pretreatment failed to be protective against MTI-101-induced cell death (Fig. 23).  These 
results were consistent with no change in the levels of pDrp1 following MTI-101 treatment in 
NCI-H929 (Fig. 22B).  Finally, reducing the expression of Rip3 did not switch the mode of cell 
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death to apoptosis in either U226 or NCI-H929 cells (Fig. 22C).  These data indicate that MTI-
101-induced cell death is Rip1/Rip3 and Drp1 independent in NCI-H929 cells.  In summary, we 
postulate that MTI-101 induces necrotic cell death via redundant pathways and inhibiting the 
Rip1/Rip3/Drp1 induced necrosis will not be sufficient to block MTI-101-induced cell death. 
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Figure 22: Drp1 is modestly dephosphorylated in the U266, but not NCI-H929 cell lines 
upon MTI-101 treatment. Treatment with MTI-101 leads to a modest decrease in pDrp1 (S637) 
levels in U266 but not in NCI-H929 cells (A, B). To address whether inhibition of the 
necroptosome via RNAi may direct cell death toward apoptosis upon MTI-101 treatment, NCI-
H929 and U266 cells were incubated with Rip3 siRNA for 72 hours before treatment of 5uM and 
10uM MTI-101 respectively for 6 hours, and cleaved caspase-3 levels were measured by FACS 
analysis. As shown in (C), there is no difference in cleaved caspase-3 in either cell line. 
Experiments were run in triplicate and repeated 3 times. Representative Western blot is shown 
from 3 independent experiments Statistical significance using Student’s t-test, #P>0.05. 
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Figure 23: MTI-101 necrotic cell death is Rip1/Rip3 and Drp1 independent in NCI-H929 
cell line. NCI-H929 cells were incubated with siRNA targeting Rip1 (A), Rip3 (B), or Drp1 (C) 
for 72 hours before treatment of 5uM MTI-101 for 6 hours, with cell death determined by FACS 
analysis  (NS = non-silencing). (D) NCI-H929 cells were pretreated with 100uM DRP1 inhibitor 
Mdivi-1 for 1 hour before treatment with 5 µM MTI-101 for 6 hours, with cell death assessed via 
FACS analysis. NCI-H929 cells were incubated with siRNA targeting DRP1 for 72 hours before 
treatment with 5uM MTI-101 for 6 hours, with cell death assessed by FACS analysis (NS = non-
silencing) . There was no statistically significant difference in cell death upon knockdown of 
Drp1 or by pharmacologic inhibition. As shown in (A, B, C), there was no difference in cell 
death upon Rip1, Rip3, or Drp1 knockdown, suggesting that necroptosis is not involved in MTI-
101 cell death in NCI-H929. Representative Western blot is shown from 3 independent 
experiments. Knockdown and inhibitor experiments were run in triplicate and repeated 3 times. 
Statistical significance was determined using Student’s t-test, #P>0.05.  
 
MTI-101 induces mitochondrial fragmentation in MM cell lines: 
Given that we implicated Rip1, Rip3, and Drp1 to be partially involved in MTI-101 induced cell 
death, we next investigated whether MTI-101 induced mitochondrial fragmentation. NCI-H929 
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and U266 cells were incubated with 20nM Mitotracker Green FM and 0.1mg/ml PI dye for 20 
minutes and then allowed to adhere to 35 mm glass bottom microwell dishes pre-coated with 
Cell-tak. Samples were then treated with MTI-101 and immediately observed with a Leica TCS 
SP5 AOBS laser scanning confocal microscope. Time Lapse (2 minute intervals for 60 minutes) 
and Z stack (60 0.5µm thick slices) images for each sample were captured. Maximum projection 
images of individual cells at each time point were analyzed. Mitochondria fragments were then 
segmented and normalized by the total area of mitotracker staining within that cell. As shown in 
figures 24 and 25, treatment with MTI-101 resulted in an increase in mitochondrial fragment bits 
compared to vehicle control cells. Furthermore, cell death as determined by PI staining followed 
mitochondrial fragmentation (Fig. 24B and 24D). Taken together, these data further suggest that 
MTI-101 induces the necroptotic pathway. 
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Figure 24: MTI-101 induces mitochondrial fragmentation in NCI-H929 and U266 MM cell 
lines. U266 (A, B) and NCI-H929 (C, D) cells were incubated with 20nM Mitotracker Green FM 
dye and 0.1mg/ml PI for 20 minutes and then allowed to adhere to 35 mm glass bottom 
microwell dishes pre-coated with Cell-tak. Samples were then treated with 20uM and 40uM 
MTI-101 respectively and immediately observed with a Leica TCS SP5 AOBS laser scanning 
confocal microscope. Experiments were repeated 3 times. 
U266 (t=0 min) U266 (t=60 min)
NCI-H929 (t=0 min) NCI-H929 (t=60 min)
A. B.
C. D.
 
Figure 25: MTI-101 induces mitochondrial fragmentation in U266 and NCI-H929 MM cell 
lines. U266 (A, B) and NCI-H929 (C, D) cells were incubated with 20nM Mitotracker Green FM 
dye and 0.1mg/ml PI for 20 minutes and then allowed to adhere to 35 mm glass bottom 
microwell dishes pre-coated with Cell-tak. Samples were then treated with 20uM and 40uM 
MTI-101 respectively and immediately observed with a Leica TCS SP5 AOBS laser scanning 
confocal microscope. Time Lapse (2 minute intervals for 60 minutes) and Z stack (60 0.5µm 
thick slices) images for each sample were captured. Maximum projection images of individual 
cells at each time point were analyzed. Mitochondria fragments were then segmented and 
normalized by the total area of mitotracker staining within that cell. Experiments were repeated 3 
times and a representative image at time point zero and at 60 minutes are shown for each cell 
line. 
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MTI-101 inhibits myeloma tumor growth in vivo:    
We used the SCID-hu and 5TGM1 in vivo myeloma mouse models to determine if MTI-101 was 
an efficacious anti-tumor agent. The SCID-hu myeloma mouse model entails engrafting 
cadavered fetal bone into the mammary mouse pad.  Importantly the SCID-hu model considers 
drug response in the confines of the bone marrow microenvironment without systemic disease 
confounding interpretation of drug response159,160.  Thus the SCID-Hu model is ideal for 
evaluating pre-clinical drugs for the treatment of myeloma.  As shown in Figure 26A, serum 
kappa levels were significantly decreased in the MTI-101 treatment group versus controls 
(ANOVA P<0.05).  During these studies, at the doses used no overt signs of toxicity were noted.  
The 5TGM1 mouse myeloma model entails engrafted 5TGM1 cells into C57BL/KaLwRijHsd 
mice via tail vein.  At day 10, mice were treated with agents 3 times a week for 3 weeks. Mice 
were monitored daily for survival with all remaining mice euthanized at day 100 after treatment. 
As shown in Figure 26B, serum kappa levels were significantly decreased (ANOVA P<0.05) in 
the MTI-101 and bortezomib treatment groups versus controls. Additionally, MTI-101 given at 
doses of 10 and 25 mg/kg 3 times weekly demonstrated a significant increase in survival (Fig. 
26C) when compared to control animals (p=0.02 at 10 mg/kg and p=0.002 at 25 mg/kg Mantel–
Cox test). Together these data indicate that MTI-101 is efficacious as a single agent in myeloma 
in vivo model systems and warrants further development for the treatment of MM. 
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Figure 26: MTI-101 has activity as a single agent in the SCID-Hu and 5TGM1 in vivo 
mouse models. (A) In the SCID-Hu model, tumor was allowed to engraft for 28 days and mice 
were randomized into control and treatment group. On day 28, represented as day 0 on the graph 
mice (N=10 for each treatment) were treated intraperitoneally (I.P.) with 8 mg/kg of MTI-101 or 
PBS daily for 21 days. Tumor burden was assessed weekly by measuring kappa levels in the 
sera.  MTI-101 treatment demonstrated a significant reduction in tumor burden (p<0.05 
ANOVA). (B) In the 5TGM1 model, 1x106 5TGM1 cells were injected into 6-8 week old 
C57BL/KaLwRijHsd mice (N=10 for each treatment) via tail vein At day 10, mice were treated 
with agents 3 times a week for 3 weeks. IgG2B serum levels were measured by ELISA once a 
week for 4 weeks. Mice were monitored daily for survival with all remaining mice euthanized at 
day 100 after treatment. Statistical significance was determined using ANOVA, P<0.05. MTI-
101 has activity as a single agent in vivo. (C) In the 5TGM1 mouse myeloma model, tumor was 
allowed to engraft for 10 days and mice (N=10 for each treatment) were treated IP at day 10 with 
agents (MTI-101, bortezomib, or PBS) 3 times a week for 3 weeks. MTI-101 treatment resulted 
in a significant increase in survival compared to control mice (p<0.05, Mantel–Cox test). Mice 
were monitored daily for survival with all remaining mice euthanized at day 100 after treatment.  
Statistical significance was determined using ANOVA, P<0.05.   
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Chapter 5: Discussion and Future Directions 
 
Our laboratory previously showed that the novel d-amino acid peptide HYD1 induced 
caspase independent necrotic cell death, ATP depletion, mitochondrial membrane potential 
dysfunction, and ROS production in a number of MM cell lines150. Furthermore, HYD1 was 
shown to have activity in vivo as well as was found to be more potent in MM cells obtained for 
relapsed patients compared to newly diagnosed150,151. Due to these intriguing findings, we sought 
to increase the therapeutic potential of this class of compounds.  
There are a number of possible chemical modifications that can be made to a given 
compound to render it more bioactive, namely cyclization, PEGylation, or antibody 
conjugation161,162. With respect to cyclization, numerous cyclized peptides derived from natural 
products demonstrate robust bioactivity163,164. The therapeutic potential of cyclic peptides is 
thought to be the result of decreased digestion by proteases as well as constraining the peptide 
into a confirmation that shares a high affinity for its cognate receptor161,165,166. Due to these 
qualities, peptide cyclization has become an attractive strategy for drug discovery.  Certainly, 
targeting extracellular targets such as integrin-ligand and receptor-ligand interactions is attractive 
as concerns of poor intracellular accumulation are diminished.  A number of cyclized therapeutic 
agents have shown promise in the clinic, including cyclosporine, numerous antibiotics, and the 
cyclized RGD integrin binding motif, Cilengitide162,168,169. 
In the present study, we wanted to determine the minimal peptide sequence that was 
bioactive. With the assistance of the USF chemistry core facility, we obtained HYD1 peptide 
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analogs that were sequentially truncated for both the N- and C-terminus. Using a cell-based cell 
death assay, it was determined that the minimally active peptide was mvisw. This finding was 
consistent with that of Cress et al. who reported that the kmvixw peptide sequence was sufficient 
to inhibit cell adhesion149. We then took the minimally active truncated core region of HYD1 
(mvisw) and cyclized that peptide using a beta turn promoter scaffold backbone. Given that our 
peptide contained the amino acid tryptophan, it was postulated that the secondary structure that 
the peptide would most likely adopt would be a beta turn and thus the rationale for constraining 
the peptide in such a cyclized configuration. The initial sequence inserted was mvvsw which was 
subsequently optimized in the L-configuration. Valine was substituted for alanine as this was 
shown to result in a more potent analog. The solubility of mvvsw was very poor but the three 
lysines on the non-recognition strand render MTI-101 water soluble. Next, alanine substitution 
scanning of the core sequence constrained in the beta turn promoter was used to optimize the 
sequence. Substitution of alanine for tryptophan was shown to reduce bioactivity, while 
substitution of alanine for serine as well as nor-leucine for methionine resulted in a more active 
peptide. In this report, the most potent analog (MTI-101), contained the optimized sequence 
NLeVVAW comprised of all L-amino acid peptides within the beta turn promoter scaffold 
backbone and was used for all subsequent studies. MTI-101was found to be 6-10-fold more 
potent than the linear parent peptide in vitro. 
Previously, we demonstrated that HYD1 induced autophagy and caspase independent 
necrotic cell death in myeloma cell lines via ATP depletion, ROS production, and mitochondrial 
membrane potential dysfunction150. In the present study, we investigated whether the optimized 
analog MTI-101 would act in a similar manner to the parent compound. As with HYD1, MTI-
101 treatment resulted in caspase independent cell death, ATP depletion, and the generation of 
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ROS in MM cell lines. Furthermore, MTI-101 was found to be cross-resistant in the acquired 
HYD1 resistant cell line H929-60. Together, these data suggest that MTI-101 induced cell death 
is mechanistically similar to the parental HYD1 peptide. Although, the complete mechanism of 
action of MTI-101 induced cell death remains to be elucidated.  
Our laboratory previously implicated VLA-4 as being involved in HYD1 induced cell 
death. However, reducing the expression of α4 integrin only provided partial protection from cell 
death, thus suggesting other proteins must being involved in cell death151. In the present study, 
we sought to utilize an unbiased chemical biology approach by using biotinylated HYD1 and 
LC-MS/MS analysis as an analytical tool for defining the HYD1 binding complex. Upon data 
analysis, we identified a number of adhesion receptors in our binding complex, including α4-, 
β1-, and β7-integrin, basigin, syndecan, ICAM, NCAM, and CD44, with CD44 abundant in the 
binding complexes of both NCI-H929 and U266 cell lines. Given that LC-MS/MS can report 
false positives, we further validated CD44 as being in the biotin-HYD1 and biotin-MTI-101 
binding complexes by Western blot. 
Interested in determining if CD44 was a direct binding partner of HYD1 and MTI-101, 
we performed an ELISA-based binding assay with full-length recombinant human CD44 and 
found that biotin-HYD1 bound to CD44 in a concentration dependent manner. This observation 
was further validated in PBMCs isolated from CD44 knockout mice, which exhibited less 
binding of fluorescently labeled peptide compared to wild-type. Furthermore, we replicated this 
binding with a fluorescently labeled peptide in 8226 cells that overexpressed CD44s. 
Paradoxically, increased expression of CD44s and subsequent increased binding of the FAM-
conjugated peptide did not translate to increased cell death. The observation of increased binding 
but not increased cell death indicates that expression of CD44 expression is necessary for 
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binding but not sufficient for mediating cell death. We speculate that determinants of cell death 
will include lateral signaling through VLA-4 integrin as well as background signaling of the cell 
analogous to CD44 dependent depletion of activated T-cells. Additionally, CD44 knockout mice 
did exhibit modest peptide binding, which may suggest that we may have multiple binding 
targets. This is not usual, as the RGD sequence of FN has been reported to bind multiple 
adhesion receptors170,171,172. Finally, we targeted all isoforms of CD44 using siRNA gene 
silencing with the goal of assessing its role in MTI-101-induced cell death. Our data indicate that 
MM cell survival is dependent on CD44 expression.  To our knowledge, this was the first time 
that reduced CD44 expression in myeloma cell lines resulted in the activation of cleaved 
caspase-3. However, this finding was not entirely surprising; as depleting CD44 promoted 
apoptosis in colon cancer cells173 as well as it has been reported that CD44 may sequester the Fas 
receptor130. Therefore, by reducing CD44 expression, the Fas receptor may become active and 
induce caspase dependent cell death. However, a more likely possibility in our cells lines is that 
reduction of expression of CD44 allows for the activation of caspase-8 and caspase-10, as we 
show these proteins to co-precipitate with CD44. Finally, transient knockdown of other proteins 
found in the complex such as basigin and syndecan-1 failed to confer resistance to MTI-101 
induced cell death. Our finding suggests that CD44 may be an important mediator of cell 
viability via inhibition of apoptosis and a key regulator of activation of a necrotic cell death in 
MM cells.  Together, these observations indicate that CD44 is an excellent candidate to target 
therapeutically in MM, as is already being done in other cancers139,142,145.  
It has been reported that CD44 activation results in the association and activation of Pyk2 
during cell adhesion154-156. Our signaling data indicate that MTI-101 induces a partial agonistic 
signal as indicated by the formation of a Pyk2-CD44 complex. We did not observe any 
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consistent or robust increase in phosphorylated Pyk2 (data not shown), which may indicate that 
the peptide induces focal adhesions but does not efficiently drive autophosphorylation and 
activation of the complex. We also observed activation of the Erk/Mapk pathway.  Activation of 
the MAPK pathway has been reported to be activated by HA binding to CD44174, and thus these 
data are consistent with a partial agonist.  Similar results have been obtained with cyclic RGD 
showing that the peptide can activate αVβ3 signaling as demonstrated by activation of FAK175. 
Further studies are required to determine whether MTI-101 competes with binding for known 
endogenous ligands of CD44 such as fibronectin, ostepontin, or HA.  Thus, understanding the 
survival signal initiated by MTI-101-induced cell death may lead to rationally designed 
combination strategies for increasing the efficacy of this novel agent.   
Recently, numerous reports have indicated that cells can initiate an apoptotic-like 
programmed form of necrosis called necroptosis60,63,64. A critical mediator of necrosis is the 
serine/threonine kinase Rip1. Interested in determining if CD44 associates with proteins 
associated with necroptosis, we performed CD44 immunoprecipitation assays in MM cells 
treated with MTI-101 at various time points. We observed that CD44 co-localized with Rip1 in 
both NCI-H929 and U266 MM cells. Interestingly, this co-localization was independent of MTI-
101 and there was no consistent trend in co-localization over treatment time. In an attempt to 
further delineate necroptotic proteins involved in MTI-101 induced cell death, data obtained 
from LC-MS/MS immunoprecipitation pull-down assays were further analyzed for proteins 
reported to be involved in necroptosis. To this end, caspase-8, caspase-10, Drp1, and the c-FLIP 
analog and caspase-8 inhibitor TNFAIP8 were found to be contained within the HYD1 binding 
complex. These proteins were further validated as being associated with CD44 via Western blot. 
However, much like Rip1 there was no consistent trend in co-localization with CD44 over 
 85 
 
treatment time. Therefore, other assays such as enzymatic activity assays may be needed in order 
to show CD44 target engagement and the activation of the necroptotic pathway. Together, our 
data suggest that CD44 may be sequestering a necroptotic cell death complex and binding of 
MTI-101 may initiate the necroptotic pathway.      
In an attempt to further implicate the role of necroptosis in MTI-101 induced cell death, 
we pursued RNA silencing strategies. Using siRNA targeting Rip1, Rip3, or Drp1 (critical 
drivers of necroptosis), we observed a modest, but significant, increase in U266 cell survival 
upon MTI-101 treatment after gene knockdown in each of these proteins. When we inhibited the 
canonical necroptotic pathway by using the Drp1 inhibitor mdivi-1, we again observed a modest 
but significant increase in cell survival. Levels of serine 637 Drp1 phosphorylation were also 
decreased in U266 cells upon MTI-101 treatment. With these same experiments in NCI-H929 
myeloma cells, however, we did not observe a statistically significant difference in cell survival 
upon MTI-101 treatment. Also, mdivi-1 pretreatment failed to protect against MTI-101-induced 
cell death. We propose that similar to apoptosis, programmed necrosis is likely regulated by 
multiple family members and thus contains redundancy.  However, genotype differences 
between H929 and U226 cell lines include an activating BRAF mutation and autocrine IL-6 
stimulation and constitutive activation of STAT3 in U226 cells.  Thus differences in background 
genotype may contribute to MTI-101 induced Drp1 dependent and independent cell death176,177.  
Additionally, differential expression of a number of glucose transporters, namely GLUT4 and 
GLUT5 has been assessed in multiple myeloma cell lines, with NCI-H929 demonstrating higher 
levels of expression of these transporters when compared to U266178. Myeloma cells have also 
been reported to have high ER activity as well as a greater level of Ca+ leakage from the ER than 
that of other types of leukemia, which has been reported to sensitize these cells to mitochondrial 
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inhibitors179. Therefore, it would be tempting to speculate that the mechanism associated with 
mitochondrial fragmentation in myeloma may be related to the level of metabolic activity of each 
cell line, with NCI-H929 being more glycolytic than U266. If this were shown to be the case, it 
would follow that the NCI-H929 cell line would most likely contain higher background levels of 
ROS as a byproduct of increased metabolic function which may sensitize these cells to agents 
that may disrupt mitochondrial function. Given that ROS has also been shown to induce necrotic 
cell death independent of Drp1, it would be attractive to postulate that this is the mechanism by 
which MTI-101 induces mitochondrial fragmentation and ultimately necrotic cell death in NCI-
H929. Thus, our work in myeloma cell lines indicates that it will be important to determine the 
role of MTI-101 induced Drp1 dependent and independent cell death using primary patient 
specimens.   
Our current proposed model is MTI-101 binds a CD44 and α4 integrin containing 
complex and induces a CD44-Pyk2 complex. This complex activation leads to both a pro-
survival signal mediated through Erk1/2 and a necrotic cell signal through Rip1/Rip3, and Drp1. 
Our data also indicate that we may be activating a novel necrotic cell death pathway that has yet 
to be fully elucidated and may represent an important pathway for targeting myeloma cells (See 
Figure 27 for model of MTI-101 induced cell death and survival signals). To this end, analysis of 
our mass spectrometry data have revealed that other proteins that may be involved in necroptosis 
are contained within our binding complex, namely PGAM5, TRADD, API5, and Dynamin 2/3. 
Subsequent validation of each of these proteins will further provide insight into the mechanism 
of action of MTI-101. 
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Figure 27: Proposed model of MTI-101 induced necrotic cell death in MM. A preformed 
necroptotic death complex is associated with CD44 in the absence of ligand. Upon treatment 
MTI-101 binds a CD44/VLA-4 containing complex that results in a transient Erk1/2 survival 
signal as well as the activation of mitochondrial fragmentation through a disruption of 
mitochondrial fission/fusion homeostasis mediated by dynamin family members such as Drp1, 
OPA1, Mfn2, and dynamin 2/3 resulting in necrosis. Additionally, calcium flux may activate 
other proteins such as calcineurin and lead to Rip1/Rip3 independent necrotic cell death. 
 
Finally, MTI-101 was shown to have robust in vivo activity in the SCID-hu and 5TGM1 
myeloma models which consider the BM microenvironment. Furthermore, MTI-101 was shown 
to reduce tumor burden and prolong animal survival at a comparable rate to the standard of care 
compound bortezomib.  
Moving forward there are a number of future studies that could be performed to further 
delineate the mechanism of action of MTI-101 as well as move this compound closer to the 
clinic. The autophagy pathway that is elicited by MTI-101 needs to be further investigated. It is 
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interesting to postulate that the transient Erk1/2 signaling that is activated upon the addition of 
MTI-101 may mediate autophagy. Studies using an Erk1/2 inhibitor and subsequent investigation 
of markers of autophagy such as beclin-1 expression and the conversion of LC3I to LC3II are 
warranted. Given that autophagy promotes survival with respect to our peptide, this would be an 
interesting target for combination with MTI-101. To this end, chloroquine has been reported to 
block autophagy by preventing the acidification of the autolysosome and is currently being 
investigated in combination with other therapeutic agents45. Preliminary studies in our laboratory 
have shown that the combination of chloroquine and MTI-101 have an additive effect on cell 
death (data not shown). Therefore, it would be of interest to investigate if this effect is also 
observed in vivo.  
While we demonstrated that CD44 binds to MTI-101 through a number of different 
approaches, it would be of interest to obtain more quantitative affinity and kinetic data. To this 
end, our laboratory is currently in the process of producing the human and murine CD44 
ectodomain through an e. coli expression system. While we have obtained some purified protein, 
the current methods utilized are grossly inefficient and batch to batch variability has led to 
nonfunctional protein. This is most likely due to not only the complexity of the protein, but also 
the expression system being used. There have been numerous reports of recombinant proteins 
being expressed via mammalian expression systems and therefore provide an alternative method 
which will are currently pursuing180,181. Successful production of the CD44 ectodomain could not 
only provide affinity data, but also provide MTI-101 docking data to CD44 via x-ray 
crystallography. Furthermore, given that MTI-101 may have multiple binding targets, it would 
be of interest to perform small scale ELISA binding assays of other adhesion molecules found in 
our binding complex such as α4-, β1-, and β7-integrin, basigin, syndecan, ICAM and NCAM. 
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Additionally, if it was found that MTI-101 binds to CD44 in the Link domain which is highly 
conserved among the hyaladherin superfamily of adhesion receptors, we could retroactively 
search our LC-MS/MS data for other members that may have an affinity for MTI-101. Finally, 
expression of CD44 mutants that lack critical cytoplasmic tail amino acids could be performed to 
further delineate the proteins directly associated with CD44.  
With respect to the necroptotic pathway being initiated by MTI-101, there are a number 
of future experiments that need to be conducted to further solidify the mechanism of action. 
While we demonstrated that MTI-101 induces mitochondrial fragmentation and reduction of 
Rip1, Rip3, and Drp1 resulted in partial protection from cell death, we have yet to directly 
demonstrate the fragmentation is Drp1 dependent. Therefore, a set of experiments that show the 
translocation of Drp1 from the cytosol to the mitchondria upon the addition of MTI-101 are 
necessary. Furthermore, the use of the Drp1 inhibitor mdivi-1 in the presence of MTI-101 should 
be sufficient to show some protection from cell death if Drp1 is involved. It is tempting to 
speculate that other dynamin family members may be able to compensate for Drp1 when it is 
inhibited, as may be the case in the NCI-H929 cell line that failed to show protection to MTI-101 
upon the reduction in expression of Rip1, Rip3, or Drp1. In this case, a multiple siRNA gene 
knockdown may be needed to observe protection from MTI-101 induced cell death. 
Additionally, other critical mediators of necroptosis such as PGAM5 and MLKL need to be 
investigated in the context of MTI-101. Moreover, in addition to Rip1/Rip3 mediated 
necroptosis, Drp1 can be activated by ROS and Ca+63,64. Given that MTI-101 induces the 
generation of ROS and Ca+ flux, a set of experiments looking at mitochondrial fragmentation 
using a ROS scavenger as well as an inhibitor that blocks Ca+ flux in the presence of MTI-101 is 
warranted. Finally, given that we could not demonstrate any consistent change in the expression 
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of necroptotic proteins associated with CD44 upon the addition of MTI-101, a series of 
enzymatic activity assays would likely be informative as to which proteins are being activated by 
our peptide. 
It has been known for quite some time that mitochondrial fragmentation can also occur in 
apoptotic cells182. However, blocking the activity of Drp1 could not prevent apoptosis; only 
delay the onset thereby suggesting that mitochondrial fragmentation is an early event in the cell 
death pathway183. Furthermore, the Bcl-2 family members Bax, Bak, Bim, and Bmf which have 
been traditionally thought of players of the apoptotic pathway have also been shown to be 
involved in necrosis as well. More specifically, it has been reported that Bax and Bak can 
physically interact with and promote sumolyation of Drp1. These events have been reported to 
prevent Drp1 from leaving the mitochondria, leading to oligomerization and the induction of 
mitochondrial fragmentation184. Further evidence for a role of Bax and Bak in mitochondrial 
network modulation was demonstrated in HeLa cells overexpressing each of these proteins185. In 
these studies treatment of Bax and Bak overexpressing HeLa cells with the apoptotic agents 
actinomycin, TPCK, or DCI resulted in an increased mitochondrial fragmentation and cell death. 
However, while overexpression of the mitochondrial fusion proteins Mfn2 and OPA1 resulted in 
enhanced mitochondrial fusion, this failed to block apopotosis and the release of cytochrome c. 
Together these data suggest that Bax and Bak contribute to mitochondria morphology and 
remodeling. Bmf and Bim have also been reported to be involved in necrosis. The role of Bmf in 
necrosis was discovered using a global siRNA screen in L929 cells treated with either TNF or 
FasL in combination of zVAD186. In this study 432 genes were identified as being involved in 
necrosis. Further analysis showed that 25 genes were required for necrosis, but not apoptosis. 
Among these was the Bcl-2 family member Bmf, which has traditionally been thought of as a 
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pro-apoptotic protein. Interestingly, reduction of Bmf expression blocked necrosis, but not 
apoptosis which suggests that depending on the cell context, Bmf activation can lead to either 
apoptosis or necrosis. The Bcl-2 family member Bim has also been shown to play a role in 
necrosis. More specifically, it was shown that T-cells from Bim null mice that lacked caspase-8 
exhibited higher levels of necrosis than wild-type and inhibited the development of autoimmune 
disease187. Therefore, these data suggest that Bim may act as a negative regulator of necrosis 
much like that of caspase-8. Together, these data suggest that Bax, Bak, Bmf, and Bim may 
modulate the necrotic cell death pathway and it would be of great interest to investigate the 
possible role these proteins may play with respect to MTI-101 induced cell death in myeloma. 
Lastly, more in vivo studies with MTI-101 are needed. Given that current strategies for 
the treatment of MM is multifaceted, any therapeutic potential of MTI-101 will most likely be in 
the context of combination with other currently used agents. Therefore, it is imperative to assess 
the combined in vivo effects of MTI-101 with other agents currently used in the clinic. To this 
end, our laboratory is currently investigating combination of MTI-101 with bortezomib and 
melphalan. Additionally, biomarkers of sensitivity are needed for MTI-101. We have previously 
shown that MTI-101 is more active in MM cells isolated from relapsed patients compared to 
newly diagnosed. Furthermore, the expression of α4 integrin was correlated with HYD1 induced 
cell death in these patient cells and therefore may provide a marker of sensitivity. Preliminary 
data from patient specimens show a similar correlation with CD44, but more samples are needed 
to make a definitive statement. Additional studies such as microarray analysis on patient 
specimens as well as the use of the HYD1 acquired resistant H929-60 cell line will also provide 
another avenue to identify potential biomarkers for MTI-101 sensitivity. In conclusion, we 
demonstrated that MTI-101, through cyclization and optimization is mechanistically similar to 
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HYD1, binds to CD44, and may initiate a novel necroptotic pathway. Furthermore, this peptide 
demonstrates robust in vivo activity. Taken together, these results definitively support continued 
development of MTI-101 for the treatment of myeloma, thus providing another therapeutic 
option for this currently incurable disease. 
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